

Peter R Rossing

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3128695/publications.pdf>

Version: 2024-02-01

607
papers

45,728
citations

2669

95
h-index

3021

188
g-index

633
all docs

633
docs citations

633
times ranked

31817
citing authors

#	ARTICLE	IF	CITATIONS
1	2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. <i>European Heart Journal</i> , 2020, 41, 255-323.	1.0	2,811
2	Dapagliflozin in Patients with Chronic Kidney Disease. <i>New England Journal of Medicine</i> , 2020, 383, 1436-1446.	13.9	2,523
3	Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetes Care</i> , 2018, 41, 2669-2701.	4.3	2,190
4	New Creatinine- and Cystatin Câ€“Based Equations to Estimate GFR without Race. <i>New England Journal of Medicine</i> , 2021, 385, 1737-1749.	13.9	1,236
5	Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2020, 383, 2219-2229.	13.9	1,148
6	Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetologia</i> , 2018, 61, 2461-2498.	2.9	1,002
7	Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. <i>Lancet, The</i> , 2012, 380, 1662-1673.	6.3	984
8	2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetes Care</i> , 2020, 43, 487-493.	4.3	846
9	KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. <i>Kidney International</i> , 2020, 98, S1-S115.	2.6	692
10	Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. <i>Kidney International</i> , 2011, 79, 1331-1340.	2.6	609
11	Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2021, 385, 2252-2263.	13.9	599
12	A catalog of genetic loci associated with kidney function from analyses of a million individuals. <i>Nature Genetics</i> , 2019, 51, 957-972.	9.4	549
13	Diabetic kidney disease. <i>Nature Reviews Disease Primers</i> , 2015, 1, 15018.	18.1	542
14	Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 884.	3.8	523
15	Diabetes and Hypertension: A Position Statement by the American Diabetes Association. <i>Diabetes Care</i> , 2017, 40, 1273-1284.	4.3	462
16	Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. <i>Lancet, The</i> , 2019, 393, 1937-1947.	6.3	408
17	Predictors of mortality in insulin dependent diabetes: 10 year observational follow up study. <i>BMJ: British Medical Journal</i> , 1996, 313, 779-784.	2.4	382
18	Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis. <i>Lancet, The</i> , 2012, 380, 1649-1661.	6.3	378

#	ARTICLE	IF	CITATIONS
19	Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21Åyears follow-up on the Steno-2 randomised trial. <i>Diabetologia</i> , 2016, 59, 2298-2307.	2.9	378
20	2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetologia</i> , 2020, 63, 221-228.	2.9	368
21	Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. <i>European Heart Journal</i> , 2022, 43, 474-484.	1.0	341
22	Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort study. <i>BMJ: British Medical Journal</i> , 2004, 328, 1105.	2.4	337
23	Prevalence of micro- and macroalbuminuria, arterial hypertension, retinopathy and large vessel disease in European Type 2 (non-insulin-dependent) diabetic patients. <i>Diabetologia</i> , 1991, 34, 655-661.	2.9	332
24	Decreasing Incidence of Severe Diabetic Microangiopathy in Type 1 Diabetes. <i>Diabetes Care</i> , 2003, 26, 1258-1264.	4.3	325
25	Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 22-31.	5.5	287
26	Progression of diabetic nephropathy. <i>Kidney International</i> , 2001, 59, 702-709.	2.6	283
27	Recommendations for Biomarker Identification and Qualification in Clinical Proteomics. <i>Science Translational Medicine</i> , 2010, 2, 46ps42.	5.8	273
28	Progression of nephropathy in type 2 diabetic patients. <i>Kidney International</i> , 2004, 66, 1596-1605.	2.6	270
29	Urinary Proteomics in Diabetes and CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2008, 19, 1283-1290.	3.0	267
30	Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. <i>Kidney International</i> , 2000, 57, 601-606.	2.6	250
31	Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 597-609.	5.5	248
32	Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes. <i>New England Journal of Medicine</i> , 2020, 382, 2493-2503.	13.9	228
33	Urinary Proteomics for Early Diagnosis in Diabetic Nephropathy. <i>Diabetes</i> , 2012, 61, 3304-3313.	0.3	221
34	New Susceptibility Loci Associated with Kidney Disease in Type 1 Diabetes. <i>PLoS Genetics</i> , 2012, 8, e1002921.	1.5	216
35	Aldosterone escape during blockade of the renin?angiotensin?aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. <i>Diabetologia</i> , 2004, 47, 1936-1939.	2.9	214
36	Risk Factors for Development of Incipient and Overt Diabetic Nephropathy in Type 1 Diabetic Patients: A 10-year prospective observational study. <i>Diabetes Care</i> , 2002, 25, 859-864.	4.3	209

#	ARTICLE	IF	CITATIONS
37	Diagnosis and Prediction of CKD Progression by Assessment of Urinary Peptides. Journal of the American Society of Nephrology: JASN, 2015, 26, 1999-2010.	3.0	205
38	Higher Plasma Levels of Advanced Glycation End Products Are Associated With Incident Cardiovascular Disease and All-Cause Mortality in Type 1 Diabetes. Diabetes Care, 2011, 34, 442-447.	4.3	202
39	Diagnosis of diabetic kidney disease: state of the art and future perspective. Kidney International Supplements, 2018, 8, 2-7.	4.6	202
40	Beneficial impact of spironolactone in diabetic nephropathy. Kidney International, 2005, 68, 2829-2836.	2.6	201
41	Serum Uric Acid as a Predictor for Development of Diabetic Nephropathy in Type 1 Diabetes. Diabetes, 2009, 58, 1668-1671.	0.3	194
42	Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: evidence-based advances in monitoring and treatment. Kidney International, 2020, 98, 839-848.	2.6	193
43	Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney International, 2006, 70, 536-542.	2.6	189
44	Lack of Relationship Between an Insertion/Deletion Polymorphism in the Angiotensin Converting Enzyme Gene and Diabetic Nephropathy and Proliferative Retinopathy in IDDM Patients. Diabetes, 1995, 44, 489-494.	0.3	184
45	A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney International, 2021, 100, 215-224.	2.6	182
46	Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial. Lancet Diabetes and Endocrinology, 2019, 7, 515-527.	5.5	180
47	Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment. Diabetologia, 1994, 37, 511-516.	2.9	179
48	Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes. Circulation, 2021, 143, 540-552.	1.6	171
49	Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial. Nephrology Dialysis Transplantation, 2020, 35, 274-282.	0.4	168
50	Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial. Lancet Diabetes and Endocrinology, 2020, 8, 301-312.	5.5	166
51	Prevalence of Arterial Hypertension in Diabetic Patients Before and After the JNC-V. Diabetes Care, 1994, 17, 1247-1251.	4.3	162
52	Fast renal decline to end-stage renal disease: an unrecognized feature of nephropathy in diabetes. Kidney International, 2017, 91, 1300-1311.	2.6	159
53	Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical Trial. Diabetes Care, 2016, 39, 222-230.	4.3	158
54	Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme: observational follow up study. BMJ: British Medical Journal, 1996, 313, 591-594.	2.4	158

#	ARTICLE	IF	CITATIONS
55	Cardiac Autonomic Neuropathy Predicts Cardiovascular Morbidity and Mortality in Type 1 Diabetic Patients With Diabetic Nephropathy. <i>Diabetes Care</i> , 2006, 29, 334-339.	4.3	156
56	Long-Term Effect of Lisinopril and Atenolol on Kidney Function in Hypertensive NIDDM Subjects With Diabetic Nephropathy. <i>Diabetes</i> , 1997, 46, 1182-1188.	0.3	153
57	Prolonged QTc interval predicts mortality in patients with Type 1 diabetes mellitus. <i>Diabetic Medicine</i> , 2001, 18, 199-205.	1.2	152
58	Implementation of proteomic biomarkers: making it work. <i>European Journal of Clinical Investigation</i> , 2012, 42, 1027-1036.	1.7	151
59	Diabetic Nephropathy: Worldwide epidemic and effects of current treatment on natural history. <i>Current Diabetes Reports</i> , 2006, 6, 479-483.	1.7	148
60	Renal Effects of Aliskiren Compared With and in Combination With Irbesartan in Patients With Type 2 Diabetes, Hypertension, and Albuminuria. <i>Diabetes Care</i> , 2009, 32, 1873-1879.	4.3	147
61	Global Changes in Food Supply and the Obesity Epidemic. <i>Current Obesity Reports</i> , 2016, 5, 449-455.	3.5	143
62	Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 429-441.	5.5	137
63	A Genome-Wide Association Study of Diabetic Kidney Disease in Subjects With Type 2 Diabetes. <i>Diabetes</i> , 2018, 67, 1414-1427.	0.3	136
64	Genome-Wide Association Study of Diabetic Kidney Disease Highlights Biology Involved in Glomerular Basement Membrane Collagen. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 2000-2016.	3.0	135
65	Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis. <i>BMC Nephrology</i> , 2016, 17, 127.	0.8	134
66	Impact of Arterial Blood Pressure and Albuminuria on the Progression of Diabetic Nephropathy in IDDM Patients. <i>Diabetes</i> , 1993, 42, 715-719.	0.3	129
67	A urinary peptide biomarker set predicts worsening of albuminuria in type 2 diabetes mellitus. <i>Diabetologia</i> , 2013, 56, 259-267.	2.9	128
68	Uric Acid Lowering to Prevent Kidney Function Loss in Diabetes: The Preventing Early Renal Function Loss (PERL) Allopurinol Study. <i>Current Diabetes Reports</i> , 2013, 13, 550-559.	1.7	127
69	Vitamin D Levels and Mortality in Type 2 Diabetes. <i>Diabetes Care</i> , 2010, 33, 2238-2243.	4.3	126
70	Serum adiponectin predicts all-cause mortality and end stage renal disease in patients with type 1 diabetes and diabetic nephropathy. <i>Kidney International</i> , 2008, 74, 649-654.	2.6	124
71	Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes. <i>Kidney International</i> , 2008, 73, 1419-1425.	2.6	121
72	Plasma Concentration of Asymmetric Dimethylarginine (ADMA) Predicts Cardiovascular Morbidity and Mortality in Type 1 Diabetic Patients With Diabetic Nephropathy. <i>Diabetes Care</i> , 2008, 31, 747-752.	4.3	121

#	ARTICLE	IF	CITATIONS
73	Urinary proteomic diagnosis of coronary artery disease: identification and clinical validation in 623 individuals. <i>Journal of Hypertension</i> , 2010, 28, 2316-2322.	0.3	119
74	Exome sequencing-driven discovery of coding polymorphisms associated with common metabolic phenotypes. <i>Diabetologia</i> , 2013, 56, 298-310.	2.9	119
75	Urine and plasma metabolites predict the development of diabetic nephropathy in individuals with Type 2 diabetes mellitus. <i>Diabetic Medicine</i> , 2014, 31, 1138-1147.	1.2	119
76	YKL-40, a Marker of Inflammation and Endothelial Dysfunction, Is Elevated in Patients With Type 1 Diabetes and Increases With Levels of Albuminuria. <i>Diabetes Care</i> , 2009, 32, 323-328.	4.3	117
77	Multicentric Validation of Proteomic Biomarkers in Urine Specific for Diabetic Nephropathy. <i>PLoS ONE</i> , 2010, 5, e13421.	1.1	117
78	Pregnancy and progression of diabetic nephropathy. <i>Diabetologia</i> , 2002, 45, 36-41.	2.9	115
79	Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Kidney Injury Molecule 1 (KIM1) in patients with diabetic nephropathy: a cross-sectional study and the effects of lisinopril. <i>Diabetic Medicine</i> , 2010, 27, 1144-1150.	1.2	111
80	Development and validation of GFR-estimating equations using diabetes, transplant and weight. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 449-457.	0.4	111
81	Diabetes Management in Chronic Kidney Disease: Synopsis of the 2020 KDIGO Clinical Practice Guideline. <i>Annals of Internal Medicine</i> , 2021, 174, 385-394.	2.0	110
82	Unchanged Incidence of Diabetic Nephropathy in IDDM Patients. <i>Diabetes</i> , 1995, 44, 739-743.	0.3	109
83	Higher Plasma Soluble Receptor for Advanced Glycation End Products (sRAGE) Levels Are Associated With Incident Cardiovascular Disease and All-Cause Mortality in Type 1 Diabetes. <i>Diabetes</i> , 2010, 59, 2027-2032.	0.3	109
84	The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1700-1711.	0.4	107
85	Effective Antihypertensive Treatment Postpones Renal Insufficiency in Diabetic Nephropathy. <i>American Journal of Kidney Diseases</i> , 1993, 22, 188-195.	2.1	106
86	Markers of Endothelial Dysfunction and Inflammation in Type 1 Diabetic Patients With or Without Diabetic Nephropathy Followed for 10 Years. <i>Diabetes Care</i> , 2008, 31, 1170-1176.	4.3	106
87	Urinary Liver-Type Fatty Acid-Binding Protein Predicts Progression to Nephropathy in Type 1 Diabetic Patients. <i>Diabetes Care</i> , 2010, 33, 1320-1324.	4.3	106
88	Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1563-1570.	0.4	106
89	Angiogenic microRNAs Linked to Incidence and Progression of Diabetic Retinopathy in Type 1 Diabetes. <i>Diabetes</i> , 2016, 65, 216-227.	0.3	103
90	Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephropathy in Type 2 diabetic patients with normoalbuminuria (PRIORITY): essential study design and rationale of a randomised clinical multicentre trial. <i>BMJ Open</i> , 2016, 6, e010310.	0.8	103

#	ARTICLE	IF	CITATIONS
91	The Genetic Landscape of Renal Complications in Type 1 Diabetes. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 557-574.	3.0	101
92	Angiotensin-converting enzyme inhibition in diabetic nephropathy: Ten years' experience. <i>American Journal of Kidney Diseases</i> , 1995, 26, 99-107.	2.1	99
93	Plasma Connective Tissue Growth Factor Is an Independent Predictor of End-Stage Renal Disease and Mortality in Type 1 Diabetic Nephropathy. <i>Diabetes Care</i> , 2008, 31, 1177-1182.	4.3	99
94	Arterial Stiffness Is Associated With Cardiovascular, Renal, Retinal, and Autonomic Disease in Type 1 Diabetes. <i>Diabetes Care</i> , 2013, 36, 715-721.	4.3	99
95	Progressive Decline in Estimated Glomerular Filtration Rate in Patients With Diabetes After Moderate Loss in Kidney Function—Even Without Albuminuria. <i>Diabetes Care</i> , 2019, 42, 1886-1894.	4.3	99
96	Plasma Growth Differentiation Factor-15 Independently Predicts All-Cause and Cardiovascular Mortality As Well As Deterioration of Kidney Function in Type 1 Diabetic Patients With Nephropathy. <i>Diabetes Care</i> , 2010, 33, 1567-1572.	4.3	98
97	Vitamin D Levels, Microvascular Complications, and Mortality in Type 1 Diabetes. <i>Diabetes Care</i> , 2011, 34, 1081-1085.	4.3	98
98	LeucoPatch system for the management of hard-to-heal diabetic foot ulcers in the UK, Denmark, and Sweden: an observer-masked, randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 870-878.	5.5	95
99	Predictors of mortality in patients with type 2 diabetes with or without diabetic nephropathy: a follow-up study. <i>Journal of Hypertension</i> , 2007, 25, 2479-2485.	0.3	93
100	Plasma lipoproteins and renal function during simvastatin treatment in diabetic nephropathy. <i>Diabetologia</i> , 1992, 35, 447-451.	2.9	91
101	Angiotensin converting enzyme gene polymorphism and ACE inhibition in diabetic nephropathy. <i>Kidney International</i> , 1998, 53, 1002-1006.	2.6	91
102	Tubular markers do not predict the decline in glomerular filtration rate in type 1 diabetic patients with overt nephropathy. <i>Kidney International</i> , 2011, 79, 1113-1118.	2.6	91
103	Remission and regression in the nephropathy of type 1 diabetes when blood pressure is controlled aggressively ¹ See Editorial by Steffes, p. 378. <i>Kidney International</i> , 2001, 60, 277-283.	2.6	89
104	Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, 33, 225-237.	3.0	89
105	Cyclosporine nephrotoxicity in type 1 diabetic patients. A 7-year follow-up study. <i>Diabetes Care</i> , 1999, 22, 478-483.	4.3	88
106	SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation. <i>American Journal of Kidney Diseases</i> , 2021, 77, 94-109.	2.1	88
107	Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 2352-2361.	3.0	88
108	Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER. <i>Circulation</i> , 2022, 145, 575-585.	1.6	88

#	ARTICLE	IF	CITATIONS
109	Insertion/deletion polymorphism in the angiotensin-I-converting enzyme gene is associated with coronary heart disease in IDDM patients with diabetic nephropathy. <i>Diabetologia</i> , 1995, 38, 798-803.	2.9	87
110	On the Mechanisms of Blunted Nocturnal Decline in Arterial Blood Pressure in NIDDM Patients With Diabetic Nephropathy. <i>Diabetes</i> , 1995, 44, 783-789.	0.3	87
111	QTc interval length and QT dispersion as predictors of mortality in patients with non-insulin-dependent diabetes. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2000, 60, 323-332.	0.6	87
112	Trimethylamine N-oxide (TMAO) as a New Potential Therapeutic Target for Insulin Resistance and Cancer. <i>Current Pharmaceutical Design</i> , 2017, 23, 3699-3712.	0.9	87
113	Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 743-754.	5.5	87
114	Global Longitudinal Strain Is Not Impaired in Type 1 Diabetes Patients Without Albuminuria. <i>JACC: Cardiovascular Imaging</i> , 2015, 8, 400-410.	2.3	86
115	Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 7 randomised controlled trials. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 880-893.	5.5	86
116	Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 755-766.	5.5	86
117	Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial. <i>Circulation</i> , 2022, 145, 437-447.	1.6	86
118	Effects of 12 weeks of treatment with fermented milk on blood pressure, glucose metabolism and markers of cardiovascular risk in patients with type 2 diabetes: a randomised double-blind placebo-controlled study. <i>European Journal of Endocrinology</i> , 2015, 172, 11-20.	1.9	85
119	Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular Disease. <i>Circulation</i> , 2021, 143, 438-448.	1.6	85
120	Genetics of diabetic nephropathy.. <i>Journal of the American Society of Nephrology: JASN</i> , 1996, 7, 2509-2517.	3.0	85
121	The changing epidemiology of diabetic microangiopathy in type 1 diabetes. <i>Diabetologia</i> , 2005, 48, 1439-1444.	2.9	84
122	Effect of Adjunct Metformin Treatment in Patients with Type-1 Diabetes and Persistent Inadequate Glycaemic Control. A Randomized Study. <i>PLoS ONE</i> , 2008, 3, e3363.	1.1	83
123	Prediction, progression and prevention of diabetic nephropathy. The Minkowski Lecture 2005. <i>Diabetologia</i> , 2006, 49, 11-19.	2.9	82
124	Progression of diabetic nephropathy in normotensive type 1 diabetic patients. <i>Kidney International</i> , 1999, 56, S101-S105.	2.6	80
125	Oral Contraceptives, Angiotensin-Dependent Renal Vasoconstriction, and Risk of Diabetic Nephropathy. <i>Diabetes Care</i> , 2005, 28, 1988-1994.	4.3	80
126	ACE Gene Polymorphism and Losartan Treatment in Type 2 Diabetic Patients With Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2008, 19, 771-779.	3.0	80

#	ARTICLE	IF	CITATIONS
127	Intensified multifactorial intervention in type 2 diabetics with microalbuminuria leads to long-term renal benefits. <i>Kidney International</i> , 2017, 91, 982-988.	2.6	80
128	Long-term renoprotective effect of nisoldipine and lisinopril in type 1 diabetic patients with diabetic nephropathy. <i>Diabetes Care</i> , 2000, 23, 1725-1730.	4.3	79
129	The Baltic Sea: Estimates of total fisheries removals 1950â€“2007. <i>Fisheries Research</i> , 2011, 108, 356-363.	0.9	79
130	Tubular markers are associated with decline in kidney function in proteinuric type 2 diabetic patients. <i>Diabetes Research and Clinical Practice</i> , 2012, 97, 71-76.	1.1	78
131	Low Birth Weight: A Risk Factor for Development of Diabetic Nephropathy?. <i>Diabetes</i> , 1995, 44, 1405-1407.	0.3	77
132	Irbesartan Treatment Reduces Biomarkers of Inflammatory Activity in Patients With Type 2 Diabetes and Microalbuminuria: An IRMA 2 Substudy. <i>Diabetes</i> , 2006, 55, 3550-3555.	0.3	77
133	Prediction of Chronic Kidney Disease Stage 3 by CKD273, a Urinary Proteomic Biomarker. <i>Kidney International Reports</i> , 2017, 2, 1066-1075.	0.4	77
134	The effect of liraglutide on renal function: A randomized clinical trial. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 239-247.	2.2	77
135	Utility of Plasma Concentration of Trimethylamine N-Oxide in Predicting Cardiovascular and Renal Complications in Individuals With Type 1 Diabetes. <i>Diabetes Care</i> , 2019, 42, 1512-1520.	4.3	77
136	Telomere length predicts all-cause mortality in patients with type 1 diabetes. <i>Diabetologia</i> , 2010, 53, 45-48.	2.9	76
137	Glomerular filtration rate estimation using cystatin C alone or combined with creatinine as a confirmatory test. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1195-1203.	0.4	76
138	Microalbuminuria: A parameter that has changed diabetes care. <i>Diabetes Research and Clinical Practice</i> , 2015, 107, 1-8.	1.1	75
139	The Danish Adult Diabetes Registry. <i>Clinical Epidemiology</i> , 2016, Volume 8, 429-434.	1.5	75
140	Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial. <i>European Heart Journal</i> , 2021, 42, 1216-1227.	1.0	75
141	Increased glomerular filtration rate after withdrawal of long-term antihypertensive treatment in diabetic nephropathy. <i>Kidney International</i> , 1995, 47, 1726-1731.	2.6	74
142	Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA 2) study. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2008, 68, 731-738.	0.6	74
143	Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes. <i>Journal of the American College of Cardiology</i> , 2021, 78, 142-152.	1.2	74
144	A urinary proteome-based classifier for the early detection of decline in glomerular filtration. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, gfw239.	0.4	73

#	ARTICLE	IF	CITATIONS
145	Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy. <i>Kidney International Reports</i> , 2022, 7, 36-45.	0.4	73
146	Elevated Levels of High-Molecular-Weight Adiponectin in Type 1 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 3186-3191.	1.8	71
147	Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria. <i>BMC Nephrology</i> , 2010, 11, 29.	0.8	71
148	Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study. <i>Diabetic Medicine</i> , 2012, 29, e184-90.	1.2	71
149	Prevalence of systolic and diastolic dysfunction in patients with type 1 diabetes without known heart disease: the Thousand & 1 Study. <i>Diabetologia</i> , 2014, 57, 672-680.	2.9	71
150	Improved prognosis in type 1 diabetic patients with nephropathy: A prospective follow-up study. <i>Kidney International</i> , 2005, 68, 1250-1257.	2.6	70
151	Plasma osteoprotegerin levels predict cardiovascular and all-cause mortality and deterioration of kidney function in type 1 diabetic patients with nephropathy. <i>Diabetologia</i> , 2008, 51, 2100-2107.	2.9	70
152	Lack of relationship between an insertion/deletion polymorphism in the angiotensin I-converting enzyme gene and diabetic nephropathy and proliferative retinopathy in IDDM patients. <i>Diabetes</i> , 1995, 44, 489-494.	0.3	70
153	Macro-microangiopathy and endothelial dysfunction in NIDDM patients with and without diabetic nephropathy. <i>Diabetologia</i> , 1996, 39, 1590-1597.	2.9	69
154	Increased sympathetic activity during sleep and nocturnal hypertension in Type 2 diabetic patients with diabetic nephropathy. <i>Diabetic Medicine</i> , 1999, 16, 555-562.	1.2	68
155	Improved Survival and Renal Prognosis of Patients With Type 2 Diabetes and Nephropathy With Improved Control of Risk Factors. <i>Diabetes Care</i> , 2014, 37, 1660-1667.	4.3	68
156	Urinary proteomics predict onset of microalbuminuria in normoalbuminuric type 2 diabetic patients, a sub-study of the DIRECT-Protect 2 study. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, gfw292.	0.4	66
157	Reduced risk of heart failure with intensified multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: 21Âyears of follow-up in the randomised Steno-2 study. <i>Diabetologia</i> , 2018, 61, 1724-1733.	2.9	66
158	Optimal dose of losartan for renoprotection in diabetic nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2002, 17, 1413-1418.	0.4	64
159	Progression of microalbuminuria in type 1 diabetes: Ten-year prospective observational study. <i>Kidney International</i> , 2005, 68, 1446-1450.	2.6	64
160	The urinary proteome in diabetes and diabetes-associated complications: New ways to assess disease progression and evaluate therapy. <i>Proteomics - Clinical Applications</i> , 2008, 2, 997-1007.	0.8	64
161	Tubular and Glomerular Injury in Diabetes and the Impact of ACE Inhibition. <i>Diabetes Care</i> , 2009, 32, 1684-1688.	4.3	64
162	Fibulin-1 Is a Marker for Arterial Extracellular Matrix Alterations in Type 2 Diabetes. <i>Clinical Chemistry</i> , 2011, 57, 1556-1565.	1.5	64

#	ARTICLE	IF	CITATIONS
163	Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. <i>Diabetes</i> , 1997, 46, 1182-1188.	0.3	64
164	Benefits of long-term antihypertensive treatment on prognosis in diabetic nephropathy. <i>Kidney International</i> , 1996, 49, 1778-1782.	2.6	63
165	Angiotensinogen Gene Polymorphisms in IDDM Patients With Diabetic Nephropathy. <i>Diabetes</i> , 1996, 45, 367-369.	0.3	63
166	Remission of Nephrotic-Range Albuminuria in Type 1 Diabetic Patients. <i>Diabetes Care</i> , 2001, 24, 1972-1977.	4.3	63
167	Cardiac ⁸² Rb PET/CT for fast and non-invasive assessment of microvascular function and structure in asymptomatic patients with type 2 diabetes. <i>Diabetologia</i> , 2016, 59, 371-378.	2.9	63
168	Higher Plasma Methylglyoxal Levels Are Associated With Incident Cardiovascular Disease in Individuals With Type 1 Diabetes: A 12-Year Follow-up Study. <i>Diabetes</i> , 2017, 66, 2278-2283.	0.3	63
169	Serum Uric Acid as a New Player in the Development of Diabetic Nephropathy. , 2011, 21, 124-127.		62
170	Soluble urokinase plasminogen activator receptor levels are elevated and associated with complications in patients with type 1 diabetes. <i>Journal of Internal Medicine</i> , 2015, 277, 362-371.	2.7	62
171	Noninvasive diagnosis of chronic kidney diseases using urinary proteome analysis. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, gfw337.	0.4	62
172	Lipidomic analysis reveals sphingomyelin and phosphatidylcholine species associated with renal impairment and all-cause mortality in type 1 diabetes. <i>Scientific Reports</i> , 2019, 9, 16398.	1.6	62
173	Time course and mechanisms of the anti-hypertensive and renal effects of liraglutide treatment. <i>Diabetic Medicine</i> , 2015, 32, 343-352.	1.2	61
174	Effects of Dapagliflozin on Volume Status When Added to Renin-Angiotensin System Inhibitors. <i>Journal of Clinical Medicine</i> , 2019, 8, 779.	1.0	61
175	Uric Acid Is an Independent Risk Factor for Decline in Kidney Function, Cardiovascular Events, and Mortality in Patients With Type 1 Diabetes. <i>Diabetes Care</i> , 2019, 42, 1088-1094.	4.3	61
176	Differences Between Nisoldipine and Lisinopril on Glomerular Filtration Rates and Albuminuria in Hypertensive IDDM Patients With Diabetic Nephropathy During the First Year of Treatment. <i>Diabetes</i> , 1997, 46, 481-487.	0.3	60
177	Long-Term Renoprotective Effects of Losartan in Diabetic Nephropathy: Interaction with ACE insertion/deletion genotype?. <i>Diabetes Care</i> , 2003, 26, 1501-1506.	4.3	60
178	Impact of Baseline Renal Function on the Efficacy and Safety of Aliskiren Added to Losartan in Patients With Type 2 Diabetes and Nephropathy. <i>Diabetes Care</i> , 2010, 33, 2304-2309.	4.3	58
179	Initial Angiotensin Receptor Blockade-Induced Decrease in Albuminuria Is Associated With Long-Term Renal Outcome in Type 2 Diabetic Patients With Microalbuminuria. <i>Diabetes Care</i> , 2011, 34, 2078-2083.	4.3	58
180	Improved prognosis of diabetic nephropathy in type 1 diabetes. <i>Kidney International</i> , 2015, 87, 417-426.	2.6	58

#	ARTICLE	IF	CITATIONS
181	Glucagon-like peptide 1 receptor agonist (GLP-1 RA): long-term effect on kidney function in patients with type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2015, 29, 670-674.	1.2	58
182	Impact of Lisinopril and Atenolol on Kidney Function in Hypertensive NIDDM Subjects With Diabetic Nephropathy. <i>Diabetes</i> , 1994, 43, 1108-1113.	0.3	57
183	Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points. <i>Seminars in Nephrology</i> , 2004, 24, 147-157.	0.6	57
184	Epicardial adipose tissue predicts incident cardiovascular disease and mortality in patients with type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2019, 18, 114.	2.7	57
185	Short stature and diabetic nephropathy. <i>BMJ: British Medical Journal</i> , 1995, 310, 296-297.	2.4	55
186	Elevated fibrinogen and the relation to acute phase response in diabetic nephropathy. <i>Thrombosis Research</i> , 1996, 81, 485-490.	0.8	53
187	Promotion, prediction and prevention of progression of nephropathy in Type 1 diabetes mellitus. , 1998, 15, 900-919.		53
188	Cardiovascular morbidity and early mortality cluster in parents of type 1 diabetic patients with diabetic nephropathy. <i>Diabetes Care</i> , 2000, 23, 30-33.	4.3	53
189	Osteoprotegerin and Mortality in Type 2 Diabetic Patients. <i>Diabetes Care</i> , 2010, 33, 2561-2566.	4.3	53
190	Aliskiren in Combination with Losartan Reduces Albuminuria Independent of Baseline Blood Pressure in Patients with Type 2 Diabetes and Nephropathy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 1025-1031.	2.2	53
191	SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation. <i>Diabetes</i> , 2021, 70, 1-16.	0.3	53
192	A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function. <i>Kidney International</i> , 2022, 101, 174-184.	2.6	53
193	Smoking and Progression of Diabetic Nephropathy in Type 1 Diabetes. <i>Diabetes Care</i> , 2003, 26, 911-916.	4.3	52
194	The use of antihypertensive agents in prevention and treatment of diabetic nephropathy. <i>Current Opinion in Nephrology and Hypertension</i> , 1994, 3, 292-300.	1.0	51
195	Higher Collagen VI Formation Is Associated With All-Cause Mortality in Patients With Type 2 Diabetes and Microalbuminuria. <i>Diabetes Care</i> , 2018, 41, 1493-1500.	4.3	51
196	Urinary Collagen Fragments Are Significantly Altered in Diabetes: A Link to Pathophysiology. <i>PLoS ONE</i> , 2010, 5, e13051.	1.1	51
197	Impact of arterial blood pressure and albuminuria on the progression of diabetic nephropathy in IDDM patients. <i>Diabetes</i> , 1993, 42, 715-719.	0.3	51
198	Circadian rhythm of arterial blood pressure and albuminuria in diabetic nephropathy. <i>Kidney International</i> , 1996, 50, 579-585.	2.6	50

#	ARTICLE	IF	CITATIONS
199	Fish Oil in Diabetic Nephropathy. <i>Diabetes Care</i> , 1996, 19, 1214-1219.	4.3	50
200	Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 1014-1023.	0.4	50
201	Apolipoprotein(a) and cardiovascular disease in Type 2 (non-insulin-dependent) diabetic patients with and without diabetic nephropathy. <i>Diabetologia</i> , 1993, 36, 438-444.	2.9	49
202	Markers of inflammation and endothelial dysfunction are associated with incident cardiovascular disease, all-cause mortality, and progression of coronary calcification in type 2 diabetic patients with microalbuminuria. <i>Journal of Diabetes and Its Complications</i> , 2016, 30, 248-255.	1.2	49
203	Improved Time in Range Over 1 Year Is Associated With Reduced Albuminuria in Individuals With Sensor-Augmented Insulin Pump-Treated Type 1 Diabetes. <i>Diabetes Care</i> , 2020, 43, 2882-2885.	4.3	49
204	Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 807-820.	1.9	49
205	Need for better diabetes treatment for improved renal outcome. <i>Kidney International</i> , 2011, 79, S28-S32.	2.6	48
206	Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 1647-1656.	0.4	48
207	Design of the COMBINATION effect of FInerenone and EMPaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE). <i>Nephrology Dialysis Transplantation</i> , 2023, 38, 894-903.	0.4	48
208	Plasma matrix metalloproteinases are associated with incident cardiovascular disease and all-cause mortality in patients with type 1 diabetes: a 12-year follow-up study. <i>Cardiovascular Diabetology</i> , 2017, 16, 55.	2.7	47
209	Data Sharing Under the General Data Protection Regulation. <i>Hypertension</i> , 2021, 77, 1029-1035.	1.3	47
210	A New Panel-Estimated GFR, Including β_2 -Microglobulin and β_2 -Trace Protein and Not Including Race, Developed in a Diverse Population. <i>American Journal of Kidney Diseases</i> , 2021, 77, 673-683.e1.	2.1	47
211	Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial. <i>Diabetes Care</i> , 2021, 44, 1894-1897.	4.3	47
212	Vitamin D Levels and Asymptomatic Coronary Artery Disease in Type 2 Diabetic Patients With Elevated Urinary Albumin Excretion Rate. <i>Diabetes Care</i> , 2012, 35, 168-172.	4.3	46
213	Acute effects of dapagliflozin on renal oxygenation and perfusion in type 1 diabetes with albuminuria: A randomised, double-blind, placebo-controlled crossover trial. <i>EClinicalMedicine</i> , 2021, 37, 100895.	3.2	45
214	The methylglyoxal-derived AGE tetrahydropyrimidine is increased in plasma of individuals with type 1 diabetes mellitus and in atherosclerotic lesions and is associated with sVCAM-1. <i>Diabetologia</i> , 2013, 56, 1845-1855.	2.9	44
215	Epicardial and pericardial adipose tissues are associated with reduced diastolic and systolic function in type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2006-2011.	2.2	44
216	Replication and cross-validation of type 2 diabetes subtypes based on clinical variables: an IMI-RHAPSODY study. <i>Diabetologia</i> , 2021, 64, 1982-1989.	2.9	44

#	ARTICLE	IF	CITATIONS
217	SORBS1 gene, a new candidate for diabetic nephropathy: results from a multi-stage genome-wide association study in patients with type 1 diabetes. <i>Diabetologia</i> , 2015, 58, 543-548.	2.9	43
218	Effect of adjunct metformin treatment on levels of plasma lipids in patients with type 1 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2009, 11, 966-977.	2.2	42
219	Abnormal echocardiography in patients with type 2 diabetes and relation to symptoms and clinical characteristics. <i>Diabetes and Vascular Disease Research</i> , 2016, 13, 321-330.	0.9	42
220	Meta-analysis uncovers genome-wide significant variants for rapid kidney function decline. <i>Kidney International</i> , 2021, 99, 926-939.	2.6	42
221	Left Ventricular Hypertrophy in Non-insulin-dependent Diabetic Patients With and Without Diabetic Nephropathy. , 1997, 14, 538-546.		41
222	Reduction of urinary connective tissue growth factor by Losartan in type 1 patients with diabetic nephropathy. <i>Kidney International</i> , 2005, 67, 2325-2329.	2.6	41
223	Glucose-Dependent Insulinotropic Polypeptide Stimulates Osteopontin Expression in the Vasculature via Endothelin-1 and CREB. <i>Diabetes</i> , 2016, 65, 239-254.	0.3	41
224	Symmetric and asymmetric dimethylarginine as risk markers of cardiovascular disease, all-cause mortality and deterioration in kidney function in persons with type 2 diabetes and microalbuminuria. <i>Cardiovascular Diabetology</i> , 2017, 16, 88.	2.7	41
225	Stratification of type 2 diabetes based on routine clinical markers. <i>Diabetes Research and Clinical Practice</i> , 2018, 141, 275-283.	1.1	41
226	Association of Birth Weight With Type 2 Diabetes and Glycemic Traits. <i>JAMA Network Open</i> , 2019, 2, e1910915.	2.8	41
227	Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by <sc>GLPâ€1 RA</sc> treatment: A subgroup analysis from the <sc>FIDELIOâ€DKD</sc> trial. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 125-134.	2.2	41
228	Improved survival in patients obtaining remission of nephrotic range albuminuria in diabetic nephropathy. <i>Kidney International</i> , 2004, 66, 1180-1186.	2.6	40
229	Methylglyoxal is associated with changes in kidney function among individuals with screenâ€detected Type 2 diabetes mellitus. <i>Diabetic Medicine</i> , 2016, 33, 1625-1631.	1.2	40
230	Systems Biologyâ€Derived Biomarkers to Predict Progression of Renal Function Decline in Type 2 Diabetes. <i>Diabetes Care</i> , 2017, 40, 391-397.	4.3	40
231	Metabolomic Assessment Reveals Alteration in Polyols and Branched Chain Amino Acids Associated With Present and Future Renal Impairment in a Discovery Cohort of 637 Persons With Type 1 Diabetes. <i>Frontiers in Endocrinology</i> , 2019, 10, 818.	1.5	40
232	Circulating Metabolites and Lipids Are Associated to Diabetic Retinopathy in Individuals With Type 1 Diabetes. <i>Diabetes</i> , 2020, 69, 2217-2226.	0.3	40
233	Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials. <i>Lancet Diabetes and Endocrinology</i> , the, 2022, 10, 24-34.	5.5	40
234	Cardiovascular Autonomic Neuropathy and Subclinical Cardiovascular Disease in Normoalbuminuric Type 1 Diabetic Patients. <i>Diabetes</i> , 2012, 61, 1822-1830.	0.3	39

#	ARTICLE	IF	CITATIONS
235	High YKL-40 levels predict mortality in patients with type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2012, 96, 84-89.	1.1	39
236	Impact of type 2 diabetes and duration of type 2 diabetes on cardiac structure and function. <i>International Journal of Cardiology</i> , 2016, 221, 114-121.	0.8	39
237	Effects of liraglutide on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: a sub-analysis of a randomized, placebo-controlled, double-blind, crossover trial. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 901-905.	2.2	39
238	Preventing Early Renal Loss in Diabetes (PERL) Study: A Randomized Double-Blinded Trial of Allopurinol—Rationale, Design, and Baseline Data. <i>Diabetes Care</i> , 2019, 42, 1454-1463.	4.3	39
239	Unchanged incidence of diabetic nephropathy in IDDM patients. <i>Diabetes</i> , 1995, 44, 739-743.	0.3	39
240	Soluble Urokinase Plasminogen Activator Receptor Predicts Cardiovascular Events, Kidney Function Decline, and Mortality in Patients With Type 1 Diabetes. <i>Diabetes Care</i> , 2019, 42, 1112-1119.	4.3	38
241	Epicardial adipose tissue: an emerging biomarker of cardiovascular complications in type 2 diabetes?. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2020, 11, 204201882092882.	1.4	38
242	Glomerular size-and charge selectivity in Type 2 (non-insulin-dependent) diabetic patients with diabetic nephropathy. <i>Diabetologia</i> , 1994, 37, 195-201.	2.9	37
243	Role of patient factors in therapy resistance to antiproteinuric intervention in nondiabetic and diabetic nephropathy. <i>Kidney International</i> , 2000, 57, S32-S37.	2.6	37
244	Arterial stiffness and endothelial dysfunction independently and synergistically predict cardiovascular and renal outcome in patients with type 1 diabetes. <i>Diabetic Medicine</i> , 2012, 29, 990-994.	1.2	37
245	The renal protective effect of angiotensin receptor blockers depends on intra-individual response variation in multiple risk markers. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 678-686.	1.1	37
246	Are human endogenous retroviruses triggers of autoimmune diseases? Unveiling associations of three diseases and viral loci. <i>Immunologic Research</i> , 2016, 64, 55-63.	1.3	37
247	Variations in Risk of End-Stage Renal Disease and Risk of Mortality in an International Study of Patients With Type 1 Diabetes and Advanced Nephropathy. <i>Diabetes Care</i> , 2019, 42, 93-101.	4.3	37
248	Angiotensin-II type 1 receptor gene polymorphism and diabetic microangiopathy. <i>Nephrology Dialysis Transplantation</i> , 1996, 11, 1019-1023.	0.4	36
249	Plasma proteome analysis of patients with type 1 diabetes with diabetic nephropathy. <i>Proteome Science</i> , 2010, 8, 4.	0.7	36
250	Prevention of microalbuminuria using early intervention with renin-angiotensin system inhibitors in patients with type 2 diabetes: A systematic review. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2016, 17, 147032031665204.	1.0	36
251	Urinary proteomics for prediction of mortality in patients with type 2 diabetes and microalbuminuria. <i>Cardiovascular Diabetology</i> , 2018, 17, 50.	2.7	36
252	Metformin and cardiorenal outcomes in diabetes: A reappraisal. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 904-915.	2.2	36

#	ARTICLE	IF	CITATIONS
253	The Kidney Protective Effects of the Sodium-Glucose Cotransporter-2 Inhibitor, Dapagliflozin, Are Present in Patients With CKD Treated With Mineralocorticoid Receptor Antagonists. <i>Kidney International Reports</i> , 2022, 7, 436-443.	0.4	36
254	The effect of the relationship between tissue-type plasminogen activator and plasminogen activator inhibitor type 1 on tissue-type plasminogen activator activity in insulin-dependent diabetes mellitus. <i>Fibrinolysis</i> , 1994, 8, 22-24.	0.5	35
255	Additive prognostic value of plasma N-terminal pro-brain natriuretic peptide and coronary artery calcification for cardiovascular events and mortality in asymptomatic patients with type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2015, 14, 59.	2.7	35
256	Vitamin D analogue therapy, cardiovascular risk and kidney function in people with Type 1 diabetes mellitus and diabetic nephropathy: a randomized trial. <i>Diabetic Medicine</i> , 2015, 32, 374-381.	1.2	35
257	Prognosis and treatment of diabetic nephropathy: Recent advances and perspectives. <i>Nephrologie Et Therapeutique</i> , 2018, 14, S31-S37.	0.2	35
258	Red cell Na ⁺ /Li ⁺ countertransport in non-insulin-dependent diabetics with diabetic nephropathy. <i>Kidney International</i> , 1991, 39, 135-140.	2.6	34
259	Multifactorial treatment increases endothelial progenitor cells in patients with type 2 diabetes. <i>Diabetologia</i> , 2010, 53, 2129-2133.	2.9	34
260	Effects of 12-weeks treatment with a proton pump inhibitor on insulin secretion, glucose metabolism and markers of cardiovascular risk in patients with type 2 diabetes: a randomised double-blind prospective placebo-controlled study. <i>Diabetologia</i> , 2013, 56, 22-30.	2.9	34
261	Effect of large weight reductions on measured and estimated kidney function. <i>BMC Nephrology</i> , 2017, 18, 52.	0.8	34
262	Rationale, Design, and Baseline Characteristics of ARTS-DN: A Randomized Study to Assess the Safety and Efficacy of Finerenone in Patients with Type 2 Diabetes Mellitus and a Clinical Diagnosis of Diabetic Nephropathy. <i>American Journal of Nephrology</i> , 2014, 40, 572-581.	1.4	33
263	Prognostic clinical and molecular biomarkers of renal disease in type 2 diabetes. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, iv86-iv95.	0.4	33
264	Epicardial, pericardial and total cardiac fat and cardiovascular disease in type 2 diabetic patients with elevated urinary albumin excretion rate. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 1517-1524.	0.8	33
265	Lisinopril improves endothelial dysfunction in hypertensive NIDDM subjects with diabetic nephropathy. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 1997, 57, 427-434.	0.6	32
266	Optimal dose of lisinopril for renoprotection in type 1 diabetic patients with diabetic nephropathy: a randomised crossover trial. <i>Diabetologia</i> , 2009, 52, 46-49.	2.9	32
267	IGFBP-4 Fragments as Markers of Cardiovascular Mortality in Type 1 Diabetes Patients With and Without Nephropathy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 3032-3040.	1.8	32
268	Metformin in adults with type 1 diabetes: Design and methods of REDucing Metformin Vascular Adverse Lesions (REMOVAL): an international multicentre trial. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 509-516.	2.2	32
269	Genome-wide association study of circulating interleukin 6 levels identifies novel loci. <i>Human Molecular Genetics</i> , 2021, 30, 393-409.	1.4	32
270	Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 1261-1269.	0.4	32

#	ARTICLE	IF	CITATIONS
271	Retinopathy and clinical outcomes in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia. <i>BMJ Open Diabetes Research and Care</i> , 2014, 2, e000011.	1.2	31
272	Apolipoprotein(a) in insulin-dependent diabetic patients with and without diabetic nephropathy. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 1992, 52, 513-521.	0.6	30
273	Renoprotective effects of losartan in diabetic nephropathy: Interaction with ACE insertion/deletion genotype?. <i>Kidney International</i> , 2002, 62, 192-198.	2.6	30
274	Optimal antiproteinuric dose of aliskiren in type 2 diabetes mellitus: a randomised crossover trial. <i>Diabetologia</i> , 2010, 53, 1576-1580.	2.9	30
275	Soluble CD40 ligand is elevated in Type 1 diabetic nephropathy but not predictive of mortality, cardiovascular events or kidney function. <i>Platelets</i> , 2010, 21, 525-532.	1.1	30
276	24-hour central aortic systolic pressure and 24-hour central pulse pressure are related to diabetic complications in type 1 diabetes – a cross-sectional study. <i>Cardiovascular Diabetology</i> , 2013, 12, 122.	2.7	30
277	Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 925-933.	5.5	30
278	Markers of Collagen Formation and Degradation Reflect Renal Function and Predict Adverse Outcomes in Patients With Type 1 Diabetes. <i>Diabetes Care</i> , 2019, 42, 1760-1768.	4.3	30
279	Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial. <i>Diabetes Care</i> , 2021, 44, 1020-1026.	4.3	30
280	On the mechanisms of blunted nocturnal decline in arterial blood pressure in NIDDM patients with diabetic nephropathy. <i>Diabetes</i> , 1995, 44, 783-789.	0.3	30
281	Increased Tissue Factor Pathway Inhibitor Activity in IDDM Patients With Nephropathy. <i>Diabetes Care</i> , 1996, 19, 441-445.	4.3	29
282	Proteomic biomarkers in diabetic nephropathy–reality or future promise?. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 2843-2845.	0.4	29
283	Higher plasma high-mobility group box 1 levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study. <i>Diabetologia</i> , 2012, 55, 2489-2493.	2.9	29
284	Predicting albuminuria response to spironolactone treatment with urinary proteomics in patients with type 2 diabetes and hypertension. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, gfw406.	0.4	29
285	Growth differentiation factor-15 and fibroblast growth factor-23 are associated with mortality in type 2 diabetes – An observational follow-up study. <i>PLoS ONE</i> , 2018, 13, e0196634.	1.1	29
286	Novel risk genes identified in a genome-wide association study for coronary artery disease in patients with type 1 diabetes. <i>Cardiovascular Diabetology</i> , 2018, 17, 61.	2.7	29
287	A novel rare CUBN variant and three additional genes identified in Europeans with and without diabetes: results from an exome-wide association study of albuminuria. <i>Diabetologia</i> , 2019, 62, 292-305.	2.9	29
288	Impact of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. <i>Diabetes</i> , 1994, 43, 1108-1113.	0.3	29

#	ARTICLE	IF	CITATIONS
289	Monitoring kidney function in diabetic nephropathy. <i>Diabetologia</i> , 1994, 37, 708-712.	2.9	28
290	Procoagulant activity and intimal dysfunction in IDDM. <i>Diabetologia</i> , 1995, 38, 73-78.	2.9	28
291	Nephropathy in Type 1 diabetes is associated with increased circulating activated platelets and platelet hyperreactivity. <i>Platelets</i> , 2009, 20, 513-519.	1.1	28
292	Quantitative iTRAQ-Based Proteomic Identification of Candidate Biomarkers for Diabetic Nephropathy in Plasma of Type 1 Diabetic Patients. <i>Clinical Proteomics</i> , 2010, 6, 105-114.	1.1	28
293	Could problems with bardoxolone methyl have been predicted?. <i>Nature Reviews Nephrology</i> , 2013, 9, 128-130.	4.1	28
294	Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial. <i>Diabetologia</i> , 2022, 65, 1085-1097.	2.9	28
295	Progression of diabetic nephropathy: Role of plasma homocysteine and plasminogen activator inhibitor-1. <i>American Journal of Kidney Diseases</i> , 2001, 38, 1376-1380.	2.1	27
296	Circulating matrix metalloproteinases are associated with arterial stiffness in patients with type 1 diabetes: pooled analysis of three cohort studies. <i>Cardiovascular Diabetology</i> , 2017, 16, 139.	2.7	27
297	A Prospective Cohort Study in Patients with Type 2 Diabetes Mellitus for Validation of Biomarkers (PROVALID) – Study Design and Baseline Characteristics. <i>Kidney and Blood Pressure Research</i> , 2018, 43, 181-190.	0.9	27
298	Gut microbiota profile and selected plasma metabolites in type 1 diabetes without and with stratification by albuminuria. <i>Diabetologia</i> , 2020, 63, 2713-2724.	2.9	27
299	NT-proBNP levels, atherosclerosis and vascular function in asymptomatic type 2 diabetic patients with microalbuminuria: peripheral reactive hyperaemia index but not NT-proBNP is an independent predictor of coronary atherosclerosis. <i>Cardiovascular Diabetology</i> , 2011, 10, 71.	2.7	26
300	Effect of 4 years subcutaneous insulin infusion treatment on albuminuria, kidney function and HbA _{1c} compared with multiple daily injections: a longitudinal follow-up study. <i>Diabetic Medicine</i> , 2015, 32, 1445-1452.	1.2	26
301	Effect of bardoxolone methyl on the urine albumin-to-creatinine ratio in patients with type 2 diabetes and stage 4 chronic kidney disease. <i>Kidney International</i> , 2019, 96, 1030-1036.	2.6	26
302	Distinct Molecular Signatures of Clinical Clusters in People With Type 2 Diabetes: An IMI-RHAPSODY Study. <i>Diabetes</i> , 2021, 70, 2683-2693.	0.3	26
303	Low birth weight. A risk factor for development of diabetic nephropathy?. <i>Diabetes</i> , 1995, 44, 1405-1407.	0.3	26
304	Polymorphisms in the Interleukin-1 Gene Cluster Do Not Contribute to the Genetic Susceptibility of Diabetic Nephropathy in Caucasian Patients With IDDM. <i>Diabetes</i> , 1997, 46, 1075-1076.	0.3	25
305	Improved visual function in IDDM patients with unchanged cumulative incidence of sight-threatening diabetic retinopathy. <i>Diabetes Care</i> , 1998, 21, 2007-2015.	4.3	25
306	Renoprotection by blocking the RAAS in diabetic nephropathy – fact or fiction?. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 2354-2357.	0.4	25

#	ARTICLE	IF	CITATIONS
307	Ambulatory Tonometric Blood Pressure Measurements in Patients with Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2012, 14, 453-456.	2.4	25
308	Central Hemodynamics Are Associated With Cardiovascular Disease and Albuminuria in Type 1 Diabetes. <i>American Journal of Hypertension</i> , 2014, 27, 1152-1159.	1.0	25
309	Urinary biomarkers are associated with incident cardiovascular disease, all-cause mortality and deterioration of kidney function in type 2 diabetic patients with microalbuminuria. <i>Diabetologia</i> , 2016, 59, 1549-1557.	2.9	25
310	Cholesterol remnants and triglycerides are associated with decreased myocardial function in patients with type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2016, 15, 137.	2.7	25
311	Predictive value of echocardiography in Type 2 diabetes. <i>European Heart Journal Cardiovascular Imaging</i> , 2019, 20, 687-693.	0.5	25
312	Long-term prevention of diabetic nephropathy: an audit. <i>Diabetologia</i> , 2008, 51, 956-961.	2.9	24
313	Elevated NT-proBNP and coronary calcium score in relation to coronary artery disease in asymptomatic type 2 diabetic patients with elevated urinary albumin excretion rate. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 3242-3249.	0.4	24
314	Vitamin D status and 5-year changes in urine albumin creatinine ratio and parathyroid hormone in a general population. <i>Endocrine</i> , 2013, 44, 473-480.	1.1	24
315	Association of the pattern recognition molecule H-ficolin with incident microalbuminuria in an inception cohort of newly diagnosed type 1 diabetic patients: an 18-year follow-up study. <i>Diabetologia</i> , 2014, 57, 2201-2207.	2.9	24
316	Plasma high-sensitivity troponin T predicts end-stage renal disease and cardiovascular and all-cause mortality in patients with type 1 diabetes and diabetic nephropathy. <i>Kidney International</i> , 2017, 92, 1242-1248.	2.6	24
317	Characteristics of high- and low-risk individuals in the <sc>PRIORITY</sc> study: urinary proteomics and mineralocorticoid receptor antagonism for prevention of diabetic nephropathy in Type 2 diabetes. <i>Diabetic Medicine</i> , 2018, 35, 1375-1382.	1.2	24
318	Effect of dapagliflozin on cardiac function in people with type 2 diabetes and albuminuria – A double blind randomized placebo-controlled crossover trial. <i>Journal of Diabetes and Its Complications</i> , 2020, 34, 107590.	1.2	24
319	Plasma Metabolomics Identifies Markers of Impaired Renal Function: A Meta-analysis of 3089 Persons with Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 2275-2287.	1.8	24
320	Serum glycated albumin predicts all-cause mortality in dialysis patients with diabetes mellitus: meta-analysis and systematic review of a predictive biomarker. <i>Acta Diabetologica</i> , 2021, 58, 81-91.	1.2	24
321	Differences between nisoldipine and lisinopril on glomerular filtration rates and albuminuria in hypertensive IDDM patients with diabetic nephropathy during the first year of treatment. <i>Diabetes</i> , 1997, 46, 481-487.	0.3	24
322	Renal protection in diabetes: an emerging role for calcium antagonists. <i>Journal of Hypertension</i> , 1996, 14, S21-S22.	0.3	23
323	Urinary renin and angiotensinogen in type 2 diabetes. <i>Journal of Hypertension</i> , 2013, 31, 1646-1652.	0.3	23
324	Presence of micro- and macroalbuminuria and the association with cardiac mechanics in patients with type 2 diabetes. <i>European Heart Journal Cardiovascular Imaging</i> , 2018, 19, 1034-1041.	0.5	23

#	ARTICLE	IF	CITATIONS
325	Urinary tubular biomarkers as predictors of kidney function decline, cardiovascular events and mortality in microalbuminuric type 2 diabetic patients. <i>Acta Diabetologica</i> , 2018, 55, 1143-1150.	1.2	23
326	Echocardiography improves prediction of major adverse cardiovascular events in a population with type 1 diabetes and without known heart disease: the Thousand & 1 Study. <i>Diabetologia</i> , 2019, 62, 2354-2364.	2.9	23
327	Uncarboxylated matrix Gla-protein: A biomarker of vitamin K status and cardiovascular risk. <i>Clinical Biochemistry</i> , 2020, 83, 49-56.	0.8	23
328	Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the <sc>FIDELIOÖDKD</sc> trial. <i>European Journal of Heart Failure</i> , 2022, 24, 996-1005.	2.9	23
329	Systems biology to battle vascular disease. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 1019-1022.	0.4	22
330	Effect of Irbesartan treatment on plasma and urinary markers of protein damage in patients with type 2 diabetes and microalbuminuria. <i>Amino Acids</i> , 2012, 42, 1627-1639.	1.2	22
331	Plasma proteomics classifiers improve risk prediction for renal disease in patients with hypertension or type 2 diabetes. <i>Journal of Hypertension</i> , 2015, 33, 2123-2132.	0.3	22
332	Increased All-Cause Mortality in Patients With Type 1 Diabetes and High-Expression Mannan-Binding Lectin Genotypes: A 12-Year Follow-up Study. <i>Diabetes Care</i> , 2015, 38, 1898-1903.	4.3	22
333	Cardiac Autonomic Function Is Associated With the Coronary Microcirculatory Function in Patients With Type 2 Diabetes. <i>Diabetes</i> , 2016, 65, 3129-3138.	0.3	22
334	Variability in response to albuminuriaÖlowering drugs: true or random?. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1197-1204.	1.1	22
335	Targeted Clinical Metabolite Profiling Platform for the Stratification of Diabetic Patients. <i>Metabolites</i> , 2019, 9, 184.	1.3	22
336	Editorial: Novel Biomarkers for Type 2 Diabetes. <i>Frontiers in Endocrinology</i> , 2019, 10, 649.	1.5	22
337	CarotidÖFemoral Pulse Wave Velocity as a Risk Marker for Development of Complications in Type 1 Diabetes Mellitus. <i>Journal of the American Heart Association</i> , 2020, 9, e017165.	1.6	22
338	Diabetes mellitus in chronic kidney disease: Biomarkers beyond HbA1c to estimate glycemic control and diabetes-dependent morbidity and mortality. <i>Journal of Diabetes and Its Complications</i> , 2020, 34, 107707.	1.2	22
339	Circulating Free Fatty Acid and Phospholipid Signature Predicts Early Rapid Kidney Function Decline in Patients With Type 1 Diabetes. <i>Diabetes Care</i> , 2021, 44, 2098-2106.	4.3	22
340	Time course of the antiproteinuric and antihypertensive effect of losartan in diabetic nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2003, 18, 293-297.	0.4	21
341	Urinary Neutrophil Gelatinase-Associated Lipocalin and Progression of Diabetic Nephropathy in Type 1 Diabetic Patients in a Four-Year Follow-Up Study. <i>Nephron Clinical Practice</i> , 2011, 118, c130-c135.	2.3	21
342	Common variant in the HMG2 gene increases susceptibility to nephropathy in patients with type 2 diabetes. <i>Diabetologia</i> , 2013, 56, 323-329.	2.9	21

#	ARTICLE	IF	CITATIONS
343	Serum amyloid A and C-reactive protein levels may predict microalbuminuria and macroalbuminuria in newly diagnosed type 1 diabetic patients. <i>Journal of Diabetes and Its Complications</i> , 2013, 27, 59-63.	1.2	21
344	Improving peptide relative quantification in MALDI-TOF MS for biomarker assessment. <i>Proteomics</i> , 2013, 13, 2967-2975.	1.3	21
345	Levels of NT-proBNP, markers of low-grade inflammation, and endothelial dysfunction during spironolactone treatment in patients with diabetic kidney disease. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2013, 14, 161-166.	1.0	21
346	suPAR level is associated with myocardial impairment assessed with advanced echocardiography in patients with type 1 diabetes with normal ejection fraction and without known heart disease or end-stage renal disease. <i>European Journal of Endocrinology</i> , 2016, 174, 745-753.	1.9	21
347	Effect of liraglutide on expression of inflammatory genes in type 2 diabetes. <i>Scientific Reports</i> , 2021, 11, 18522.	1.6	21
348	Angiotensinogen gene polymorphisms in IDDM patients with diabetic nephropathy. <i>Diabetes</i> , 1996, 45, 367-369.	0.3	21
349	Finding diabetic nephropathy biomarkers in the plasma peptidome by high-throughput magnetic bead processing and MALDI-TOF/MS analysis. <i>Proteomics - Clinical Applications</i> , 2010, 4, 697-705.	0.8	20
350	Impact of aliskiren treatment on urinary aldosterone levels in patients with type 2 diabetes and nephropathy: an AVOID substudy. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2012, 13, 118-121.	1.0	20
351	Biomarkers of inflammation and endothelial dysfunction as predictors of pulse pressure and incident hypertension in type 1 diabetes: a 20-year life-course study in an inception cohort. <i>Diabetologia</i> , 2018, 61, 231-241.	2.9	20
352	Plasma trimethylamine N-oxide and its metabolic precursors and risk of mortality, cardiovascular and renal disease in individuals with type 2-diabetes and albuminuria. <i>PLoS ONE</i> , 2021, 16, e0244402.	1.1	20
353	Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study. <i>Diabetes Care</i> , 2022, 45, e888-e897.	4.3	20
354	A polymorphism in the gene encoding carnosinase (CNDP1) as a predictor of mortality and progression from nephropathy to end-stage renal disease in type 1 diabetes mellitus. <i>Diabetologia</i> , 2010, 53, 2562-2568.	2.9	19
355	Effect of Sensor-Augmented Pump Treatment Versus Multiple Daily Injections on Albuminuria: A 1-Year Randomized Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 4181-4188.	1.8	19
356	Beneficial impact of intensified multifactorial intervention on risk of stroke: outcome of 21 years of follow-up in the randomised Steno-2 Study. <i>Diabetologia</i> , 2019, 62, 1575-1580.	2.9	19
357	Mitigating risk of aldosterone in diabetic kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2020, 29, 145-151.	1.0	19
358	Performance of Indexed and Nonindexed Estimated GFR. <i>American Journal of Kidney Diseases</i> , 2020, 76, 446-449.	2.1	19
359	Angiotensin-II type 1 receptor gene polymorphism and diabetic microangiopathy. <i>Nephrology Dialysis Transplantation</i> , 1996, 11, 1019-1023.	0.4	18
360	Lack of effect of fish oil supplementation on coagulation and transcapillary escape rate of albumin in insulin-dependent diabetic patients with diabetic nephropathy. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2001, 61, 349-356.	0.6	18

#	ARTICLE	IF	CITATIONS
361	The effect of RAAS blockade on markers of renal tubular damage in diabetic nephropathy: u-NGAL, u-KIM1 and u-LFABP. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2012, 72, 137-142.	0.6	18
362	Elevated Urinary Connective Tissue Growth Factor in Diabetic Nephropathy Is Caused by Local Production and Tubular Dysfunction. <i>Journal of Diabetes Research</i> , 2015, 2015, 1-11.	1.0	18
363	Toe-brachial index as a predictor of cardiovascular disease and all-cause mortality in people with type 2 diabetes and microalbuminuria. <i>Diabetologia</i> , 2017, 60, 1883-1891.	2.9	18
364	Effect of Liraglutide on Arterial Inflammation Assessed as [¹⁸ F]FDG Uptake in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial. <i>Circulation: Cardiovascular Imaging</i> , 2021, 14, e012174.	1.3	18
365	Genetic loci and prioritization of genes for kidney function decline derived from a meta-analysis of 62 longitudinal genome-wide association studies. <i>Kidney International</i> , 2022, 102, 624-639.	2.6	18
366	Increased Plasma Apolipoprotein(a) Levels in IDDM Patients With Diabetic Nephropathy. <i>Diabetes Care</i> , 1996, 19, 1382-1387.	4.3	17
367	Serum metabolites predict response to angiotensin II receptor blockers in patients with diabetes mellitus. <i>Journal of Translational Medicine</i> , 2016, 14, 203.	1.8	17
368	Genome-Wide Association Study of Apparent Treatment-Resistant Hypertension in the CHARGE Consortium: The CHARGE Pharmacogenetics Working Group. <i>American Journal of Hypertension</i> , 2019, 32, 1146-1153.	1.0	17
369	Guidelines and clinical practice at the primary level of healthcare in patients with type 2 diabetes mellitus with and without kidney disease in five European countries. <i>Diabetes and Vascular Disease Research</i> , 2019, 16, 47-56.	0.9	17
370	Uric acid is not associated with diabetic nephropathy and other complications in type 1 diabetes. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 659-666.	0.4	17
371	Differential and shared genetic effects on kidney function between diabetic and non-diabetic individuals. <i>Communications Biology</i> , 2022, 5, .	2.0	17
372	Placebo-Controlled Comparison of Captopril, Metoprolol, and Hydrochlorothiazide Therapy in Non - Insulin-Dependent Diabetic Patients With Primary Hypertension. <i>American Journal of Hypertension</i> , 1992, 5, 257-265.	1.0	16
373	Natural course of kidney function in Type 2 diabetic patients with diabetic nephropathy. <i>Diabetic Medicine</i> , 1999, 16, 388-394.	1.2	16
374	Birth weight - a risk factor for progression in diabetic nephropathy?. <i>Journal of Internal Medicine</i> , 2003, 253, 343-350.	2.7	16
375	Renoprotection with and without blood pressure reduction. <i>Kidney International</i> , 2005, 67, S54-S59.	2.6	16
376	Urinary adiponectin excretion rises with increasing albuminuria in type 1 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2013, 27, 604-608.	1.2	16
377	Urinary sulphate excretion and progression of diabetic nephropathy in Type 1 diabetes. <i>Diabetic Medicine</i> , 2013, 30, 563-566.	1.2	16
378	Burden of Uncontrolled Metabolic Risk Factors and Left Ventricular Structure and Function in Patients With Type 2 Diabetes Mellitus. <i>Journal of the American Heart Association</i> , 2018, 7, e008856.	1.6	16

#	ARTICLE	IF	CITATIONS
379	Cardiovascular autonomic neuropathy and bone metabolism in Type 1 diabetes. <i>Diabetic Medicine</i> , 2018, 35, 1596-1604.	1.2	16
380	Prevalence of heart failure and the diagnostic value of MR-proANP in outpatients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 736-740.	2.2	16
381	Urinary Proteomics and Precision Medicine for Chronic Kidney Disease: Current Status and Future Perspectives. <i>Proteomics - Clinical Applications</i> , 2019, 13, 1800176.	0.8	16
382	Relation of cardiac adipose tissue to coronary calcification and myocardial microvascular function in type 1 and type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2020, 19, 16.	2.7	16
383	A Validated Prediction Model for End-Stage Kidney Disease in Type 1 Diabetes. <i>Diabetes Care</i> , 2021, 44, 901-907.	4.3	16
384	Effect of 26 Weeks of Liraglutide Treatment on Coronary Artery Inflammation in Type 2 Diabetes Quantified by [64Cu]Cu-DOTATATE PET/CT: Results from the LIRAFLAME Trial. <i>Frontiers in Endocrinology</i> , 2021, 12, 790405.	1.5	16
385	Reduction in albuminuria predicts diminished progression in diabetic nephropathy. <i>Kidney International, Supplement</i> , 1994, 45, S145-9.	0.1	16
386	Doubling of serum creatinine: is it sensitive and relevant?. <i>Nephrology Dialysis Transplantation</i> , 1998, 13, 244-246.	0.4	15
387	Improved cardiorenal prognosis in diabetic nephropathy. <i>Nature Reviews Nephrology</i> , 2015, 11, 68-70.	4.1	15
388	Prognostic value of ratio of transmitral early filling velocity to early diastolic strain rate in patients with Type 2 diabetes. <i>European Heart Journal Cardiovascular Imaging</i> , 2019, 20, 1171-1178.	0.5	15
389	Reduction in albuminuria with dapagliflozin cannot be predicted by baseline clinical characteristics or changes in most other risk markers. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 720-725.	2.2	15
390	Major adverse renal events (MARE): a proposal to unify renal endpoints. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 491-497.	0.4	15
391	Concomitant diabetes with atrial fibrillation and anticoagulation management considerations. <i>European Heart Journal Supplements</i> , 2020, 22, O78-O86.	0.0	15
392	Omics“Bioinformatics in the Context of Clinical Data. <i>Methods in Molecular Biology</i> , 2011, 719, 479-497.	0.4	14
393	Osteoprotegerin and coronary artery disease in type 2 diabetic patients with microalbuminuria. <i>Cardiovascular Diabetology</i> , 2011, 10, 70.	2.7	14
394	Plasma NT-proBNP and white matter hyperintensities in type 2 diabetic patients. <i>Cardiovascular Diabetology</i> , 2012, 11, 119.	2.7	14
395	Evaluation of placental growth factor and soluble Fms-like tyrosine kinase 1 as predictors of all-cause and cardiovascular mortality in patients with Type 1 diabetes with and without diabetic nephropathy. <i>Diabetic Medicine</i> , 2012, 29, 337-344.	1.2	14
396	Characterization of renal biomarkers for use in clinical trials: effect of preanalytical processing and qualification using samples from subjects with diabetes. <i>Drug Design, Development and Therapy</i> , 2015, 9, 3191.	2.0	14

#	ARTICLE	IF	CITATIONS
397	Genetic risk factors affecting mitochondrial function are associated with kidney disease in people with Type 1 diabetes. <i>Diabetic Medicine</i> , 2015, 32, 1104-1109.	1.2	14
398	Effects of bardoxolone methyl on body weight, waist circumference and glycemic control in obese patients with type 2 diabetes mellitus and stage 4 chronic kidney disease. <i>Journal of Diabetes and Its Complications</i> , 2018, 32, 1113-1117.	1.2	14
399	Ceramides and phospholipids are downregulated with liraglutide treatment: results from the LiraFlame randomized controlled trial. <i>BMJ Open Diabetes Research and Care</i> , 2021, 9, e002395.	1.2	14
400	Clinical perspective—evolving evidence of mineralocorticoid receptor antagonists in patients with chronic kidney disease and type 2 diabetes. <i>Kidney International Supplements</i> , 2022, 12, 27-35.	4.6	14
401	Urinary Proteomics Identifies Cathepsin D as a Biomarker of Rapid eGFR Decline in Type 1 Diabetes. <i>Diabetes Care</i> , 2022, 45, 1416-1427.	4.3	14
402	Increased Plasma Concentrations of Midregional Proatrial Natriuretic Peptide Is Associated With Risk of Cardiorenal Dysfunction in Type 1 Diabetes. <i>American Journal of Hypertension</i> , 2015, 28, 772-779.	1.0	13
403	Early myocardial impairment in type 1 diabetes patients without known heart disease assessed with tissue Doppler echocardiography: The Thousand & 1 study. <i>Diabetes and Vascular Disease Research</i> , 2016, 13, 260-267.	0.9	13
404	Pulse pressure is not an independent predictor of outcome in type 2 diabetes patients with chronic kidney disease and anemia—the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT). <i>Journal of Human Hypertension</i> , 2016, 30, 46-52.	1.0	13
405	Pleiotropic effects of liraglutide treatment on renal risk factors in type 2 diabetes: Individual effects of treatment. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 162-168.	1.2	13
406	Cardiac Autonomic Function Is Associated With Myocardial Flow Reserve in Type 1 Diabetes. <i>Diabetes</i> , 2019, 68, 1277-1286.	0.3	13
407	Myocardial flow reserve assessed by cardiac 82Rb positron emission tomography/computed tomography is associated with albumin excretion in patients with Type 1 diabetes. <i>European Heart Journal Cardiovascular Imaging</i> , 2019, 20, 796-803.	0.5	13
408	Generalised arterial calcification in normoalbuminuric patients with type 1 diabetes with and without cardiovascular autonomic neuropathy. <i>Diabetes and Vascular Disease Research</i> , 2019, 16, 98-102.	0.9	13
409	Omics research in diabetic kidney disease: new biomarker dimensions and new understandings?. <i>Journal of Nephrology</i> , 2020, 33, 931-948.	0.9	13
410	Assessment of the sublingual microcirculation with the GlycoCheck system: Reproducibility and examination conditions. <i>PLoS ONE</i> , 2020, 15, e0243737.	1.1	13
411	Effects of nisoldipine and lisinopril on left ventricular mass and function in diabetic nephropathy. <i>Diabetes Care</i> , 1999, 22, 491-494.	4.3	13
412	Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study. <i>Nephrology Dialysis Transplantation</i> , 2023, 38, 372-383.	0.4	13
413	Renal Protection in Diabetes—An Emerging Role for Calcium Antagonists. <i>Cardiology</i> , 1997, 88, 56-62.	0.6	12
414	Pregnancy-associated plasma protein-A in a large cohort of Type 1 diabetic patients with and without diabetic nephropathy—a prospective follow-up study. <i>Diabetic Medicine</i> , 2007, 24, 1381-1385.	1.2	12

#	ARTICLE	IF	CITATIONS
415	Follow-up of Intensive Glucose Control in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2009, 360, 416-418.	13.9	12
416	NT-proBNP, echocardiographic abnormalities and subclinical coronary artery disease in high risk type 2 diabetic patients. <i>Cardiovascular Diabetology</i> , 2012, 11, 19.	2.7	12
417	Diabetes mellitus, hypertension and albuminuria in rural <sc>Z</sc>ambia: a hospital-based survey. <i>Tropical Medicine and International Health</i> , 2013, 18, 1080-1084.	1.0	12
418	Statins are independently associated with increased HbA1c in type 1 diabetes – The Thousand & 1 Study. <i>Diabetes Research and Clinical Practice</i> , 2016, 111, 51-57.	1.1	12
419	Associations between advanced glycation endproducts and matrix metalloproteinases and its inhibitor in individuals with type 1 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2018, 32, 325-329.	1.2	12
420	Efficacy of Long-term Remote Ischemic Conditioning on Vascular and Neuronal Function in Type 2 Diabetes Patients With Peripheral Arterial Disease. <i>Journal of the American Heart Association</i> , 2019, 8, e011779.	1.6	12
421	A marker of type VI collagen formation (PRO-C6) is associated with higher arterial stiffness in type 1 diabetes. <i>Acta Diabetologica</i> , 2019, 56, 711-712.	1.2	12
422	Genome-wide association study on coronary artery disease in type 1 diabetes suggests beta-defensin 127 as a risk locus. <i>Cardiovascular Research</i> , 2021, 117, 600-612.	1.8	12
423	The Low-Expression Variant of <i>FABP4</i> Is Associated With Cardiovascular Disease in Type 1 Diabetes. <i>Diabetes</i> , 2021, 70, 2391-2401.	0.3	12
424	Effects of Empagliflozin on Myocardial Flow Reserve in Patients With Type 2 Diabetes Mellitus: The SIMPLE Trial. <i>Journal of the American Heart Association</i> , 2021, 10, e020418.	1.6	12
425	Effects of the chymase inhibitor fulacimstat in diabetic kidney disease—results from the CADA DIA trial. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 2263-2273.	0.4	12
426	Linking Kidney and Cardiovascular Complications in Diabetes—Impact on Prognostication and Treatment: The 2019 Edwin Bierman Award Lecture. <i>Diabetes</i> , 2021, 70, 39-50.	0.3	12
427	Linking glycemic dysregulation in diabetes to symptoms, comorbidities, and genetics through EHR data mining. <i>ELife</i> , 2019, 8, .	2.8	12
428	Autoregulation of glomerular filtration rate during spironolactone treatment in hypertensive patients with type 1 diabetes: a randomized crossover trial. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 3343-3349.	0.4	11
429	Tonometric devices for central aortic systolic pressure measurements in patients with type 1 diabetes. <i>Blood Pressure Monitoring</i> , 2013, 18, 156-160.	0.4	11
430	Treatment with continuous subcutaneous insulin infusion is associated with lower arterial stiffness. <i>Acta Diabetologica</i> , 2014, 51, 955-962.	1.2	11
431	Sequential RAAS Blockade: Is It Worth the Risk?. <i>Advances in Chronic Kidney Disease</i> , 2014, 21, 159-165.	0.6	11
432	Metformin and carotid intima-media thickness in never-smokers with type <sc>1</sc> diabetes: The <sc>REMOVAL</sc> trial. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1371-1378.	2.2	11

#	ARTICLE	IF	CITATIONS
433	Circulating metabolites and molecular lipid species are associated with future cardiovascular morbidity and mortality in type 1 diabetes. <i>Cardiovascular Diabetology</i> , 2022, 21, .	2.7	11
434	Direct renin inhibition in chronic kidney disease. <i>British Journal of Clinical Pharmacology</i> , 2012, 76, n/a-n/a.	1.1	10
435	The influence of pharmaceutically induced weight changes on estimates of renal function: A patient-level pooled analysis of seven randomised controlled trials of glucose lowering medication. <i>Journal of Diabetes and Its Complications</i> , 2015, 29, 1146-1151.	1.2	10
436	Cardiac repolarization and depolarization in people with Type 1 diabetes with normal ejection fraction and without known heart disease: a caseâ€control study. <i>Diabetic Medicine</i> , 2018, 35, 1337-1344.	1.2	10
437	A Targeted Multiomics Approach to Identify Biomarkers Associated with Rapid eGFR Decline in Type 1 Diabetes. <i>American Journal of Nephrology</i> , 2020, 51, 839-848.	1.4	10
438	Cardiovascular and renal outcomes by baseline albuminuria status and renal function: Results from the <sc>LEADER</sc> randomized trial. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 2077-2088.	2.2	10
439	Describing the fecal metabolome in cryogenically collected samples from healthy participants. <i>Scientific Reports</i> , 2020, 10, 885.	1.6	10
440	Prognostic Value of Early Systolic Lengthening by Strain Imaging in Type 2 Diabetes. <i>Journal of the American Society of Echocardiography</i> , 2021, 34, 127-135.	1.2	10
441	<sc>Sodiumâ€glucose</sc> cotransporter 2 inhibitors for diabetes mellitus control after kidney transplantation: Review of the current evidence. <i>Nephrology</i> , 2021, 26, 1007-1017.	0.7	10
442	Medical therapies for prevention of cardiovascular and renal events in patients with atrial fibrillation and diabetes mellitus. <i>Europace</i> , 2021, 23, 1873-1891.	0.7	10
443	Cardiovascular prognostic value of echocardiography and N terminal pro B-type natriuretic peptide in type 1 diabetes: the Thousand & 1 Study. <i>European Journal of Endocrinology</i> , 2020, 182, 481-488.	1.9	10
444	Diabetes and Risk of Adverse Events With Calcium Antagonists. <i>Diabetes Care</i> , 1998, 21, 1779-1780.	4.3	9
445	Assessment of glomerular filtration rate in diabetic nephropathy using the plasma clearance of 51Cr-EDTA. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 1998, 58, 405-414.	0.6	9
446	Therapeutic Benefits of ACE Inhibitors and Other Antihypertensive Drugs in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2001, 24, 177-178.	4.3	9
447	Pulse wave reflection is associated with diabetes duration, albuminuria and cardiovascular disease in type 1 diabetes. <i>Acta Diabetologica</i> , 2014, 51, 973-980.	1.2	9
448	Diagnosis and treatment of early renal disease in patients with type 2 diabetes mellitus: what are the clinical needs?. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, iv1-iv5.	0.4	9
449	Retinopathy is associated with impaired myocardial function assessed by advanced echocardiography in type 1 diabetes patients â€ The Thousand & 1 Study. <i>Diabetes Research and Clinical Practice</i> , 2016, 116, 263-269.	1.1	9
450	Effect of Pancreatic Hormones on pro-Atrial Natriuretic Peptide in Humans. <i>EBioMedicine</i> , 2017, 17, 88-94.	2.7	9

#	ARTICLE	IF	CITATIONS
451	Serum uric acid and progression of diabetic nephropathy in type 1 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2018, 32, 470-473.	1.2	9
452	Application of urinary proteomics as possible risk predictor of renal and cardiovascular complications in patients with type 2-diabetes and microalbuminuria. <i>Journal of Diabetes and Its Complications</i> , 2018, 32, 1133-1140.	1.2	9
453	Pleiotropic effects of liraglutide in patients with type 2 diabetes and moderate renal impairment: Individual effects of treatment. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1261-1265.	2.2	9
454	Mendelian randomization analysis does not support causal associations of birth weight with hypertension risk and blood pressure in adulthood. <i>European Journal of Epidemiology</i> , 2020, 35, 685-697.	2.5	9
455	Hyperoxia improves autonomic function in individuals with long-duration type 1 diabetes and macroalbuminuria. <i>Diabetic Medicine</i> , 2020, 37, 1561-1568.	1.2	9
456	Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors for diabetes after solid organ transplantation. <i>Transplant International</i> , 2021, 34, 1341-1359.	0.8	9
457	Association of Coding Variants in Hydroxysteroid 17-beta Dehydrogenase 14 (HSD17B14) with Reduced Progression to End Stage Kidney Disease in Type 1 Diabetes. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 2634-2651.	3.0	9
458	Early Response in Albuminuria and Long-Term Kidney Protection during Treatment with an Endothelin Receptor Antagonist: A Prespecified Analysis from the SONAR Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 2900-2911.	3.0	9
459	Role of patient factors in therapy resistance to antiproteinuric intervention in nondiabetic and diabetic nephropathy. <i>Kidney International, Supplement</i> , 2000, 75, S32-7.	0.1	9
460	Effects of Butyrate Supplementation on Inflammation and Kidney Parameters in Type 1 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial. <i>Journal of Clinical Medicine</i> , 2022, 11, 3573.	1.0	9
461	Calcium Antagonists and the Diabetic Hypertensive Patient. <i>American Journal of Kidney Diseases</i> , 1993, 21, S47-S52.	2.1	8
462	Endothelial Progenitor Cells in Long-Standing Asymptomatic Type 1 Diabetic Patients with or without Diabetic Nephropathy. <i>Nephron Clinical Practice</i> , 2011, 118, c309-c314.	2.3	8
463	Long-Term Effects of Irbesartan Treatment and Smoking on Nucleic Acid Oxidation in Patients With Type 2 Diabetes and Microalbuminuria. <i>Diabetes Care</i> , 2011, 34, 1192-1198.	4.3	8
464	Renin angiotensin system blockade reduces urinary levels of soluble urokinase plasminogen activator receptor (suPAR) in patients with type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2016, 30, 1440-1442.	1.2	8
465	Impaired coronary microcirculation in type 2 diabetic patients is associated with elevated circulating regulatory T cells and reduced number of IL-21R+ T cells. <i>Cardiovascular Diabetology</i> , 2016, 15, 67.	2.7	8
466	Cardiac time intervals and the association with 2D-speckle-tracking, tissue Doppler and conventional echocardiography: the Thousand&1 Study. <i>International Journal of Cardiovascular Imaging</i> , 2016, 32, 789-798.	0.7	8
467	Three-phase bone scintigraphy for diagnosis of Charcot neuropathic osteoarthropathy in the diabetic foot – does quantitative data improve diagnostic value?. <i>Clinical Physiology and Functional Imaging</i> , 2017, 37, 30-36.	0.5	8
468	Liver nucleotide biosynthesis is linked to protection from vascular complications in individuals with long-term type 1 diabetes. <i>Scientific Reports</i> , 2020, 10, 11561.	1.6	8

#	ARTICLE	IF	CITATIONS
469	The effect of liraglutide and sitagliptin on oxidative stress in persons with type 2 diabetes. Scientific Reports, 2021, 11, 10624.	1.6	8
470	Faecal biomarkers in type 1 diabetes with and without diabetic nephropathy. Scientific Reports, 2021, 11, 15208.	1.6	8
471	Quetelet (body mass) index and effects of dapagliflozin in chronic kidney disease. Diabetes, Obesity and Metabolism, 2022, 24, 827-837.	2.2	8
472	Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemc outcomes. Cardiovascular Diabetology, 2022, 21, 50.	2.7	8
473	Cardiovascular Autonomic Neuropathy in Type 1 Diabetes Is Associated With Disturbances in TCA, Lipid, and Glucose Metabolism. Frontiers in Endocrinology, 2022, 13, 831793.	1.5	8
474	Fibrinolysis in insulin-dependent diabetic patients with and without nephropathy. Fibrinolysis, 1996, 10, 331-335.	0.5	7
475	Effects of nisoldipine and lisinopril on microvascular dysfunction in hypertensive Type I diabetes patients with nephropathy. Clinical Science, 1998, 95, 709-717.	1.8	7
476	The CTGF -945GC polymorphism is not associated with plasma CTGF and does not predict nephropathy or outcome in type 1 diabetes. Journal of Negative Results in BioMedicine, 2011, 10, 4.	1.4	7
477	Self-reported dyspnea is associated with impaired global longitudinal strain in ambulatory type 1 diabetes patients with normal ejection fraction and without known heart disease – The Thousand & 1 Study. Journal of Diabetes and Its Complications, 2016, 30, 928-934.	1.2	7
478	Pooled Analysis of Multiple Crossover Trials To Optimize Individual Therapy Response to Renin-Angiotensin-Aldosterone System Intervention. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 1804-1813.	2.2	7
479	MR-proANP and incident cardiovascular disease in patients with type 2 diabetes with and without heart failure with preserved ejection fraction. Cardiovascular Diabetology, 2020, 19, 180.	2.7	7
480	Post-Systolic Shortening by Speckle Tracking Echocardiography Predicts Cardiac Events in Type 2 Diabetes. JACC: Cardiovascular Imaging, 2020, 13, 1289-1291.	2.3	7
481	Visit-to-visit variability of clinical risk markers in relation to long-term complications in type 1 diabetes. Diabetic Medicine, 2021, 38, e14459.	1.2	7
482	Urinary peptidome and diabetic retinopathy in the DIRECT-Protect 1 and 2 trials. Diabetic Medicine, 2021, 38, e14634.	1.2	7
483	Liraglutide reduces cardiac adipose tissue in type 2 diabetes: A secondary analysis of the LIRAFLAME randomized placebo-controlled trial. Diabetes, Obesity and Metabolism, 2021, 23, 2651-2659.	2.2	7
484	Cause-Specific Mortality According to Urine Albumin Creatinine Ratio in the General Population. PLoS ONE, 2014, 9, e93212.	1.1	7
485	Cardiovascular autonomic neuropathy and the impact on progression of diabetic kidney disease in type 1 diabetes. BMJ Open Diabetes Research and Care, 2021, 9, e002289.	1.2	7
486	Precision diagnostic approach to predict 5-year risk for microvascular complications in type 1 diabetes. EBioMedicine, 2022, 80, 104032.	2.7	7

#	ARTICLE	IF	CITATIONS
487	Aldosterone synthase (CYP11B2) 344T/C polymorphism and renoprotective response to losartan treatment in diabetic nephropathy. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2006, 66, 173-180.	0.6	6
488	Irbesartan treatment does not influence plasma levels of the advanced glycation end products N ^ε (1-carboxymethyl)lysine and N ^ε (1-carboxyethyl)lysine in patients with type 2 diabetes and microalbuminuria. A randomized controlled trial. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 3573-3577.	0.4	6
489	Cuff inflations do not affect night-time blood pressure. <i>Blood Pressure Monitoring</i> , 2015, 20, 369-372.	0.4	6
490	High osteoprotegerin is associated with development of foot ulcer in type 1 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2016, 30, 1603-1608.	1.2	6
491	Incident microalbuminuria and complement factor mannan-binding lectin-associated protein 19 in people with newly diagnosed type 1 diabetes. <i>Diabetes/Metabolism Research and Reviews</i> , 2017, 33, e2895.	1.7	6
492	Effect of weight reductions on estimated kidney function: Post-hoc analysis of two randomized trials. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 1164-1168.	1.2	6
493	The effect of uric acid lowering treatment on albuminuria and renal function in Type 1 diabetes: a randomized clinical trial. <i>Diabetic Medicine</i> , 2018, 35, 392-393.	1.2	6
494	Arterial-ventricular coupling in type 1 diabetes: arterial stiffness is associated with impaired global longitudinal strain in type 1 diabetes patients – the Thousand & 1 Study. <i>Acta Diabetologica</i> , 2018, 55, 21-29.	1.2	6
495	Type 1 diabetes is associated with T-wave morphology changes. The Thousand & 1 Study. <i>Journal of Electrocardiology</i> , 2018, 51, S72-S77.	0.4	6
496	Persons with type 1 diabetes have low blood oxygen levels in the supine and standing body positions. <i>BMJ Open Diabetes Research and Care</i> , 2021, 9, e001944.	1.2	6
497	Identification of possible adverse drug reactions in clinical notes: The case of glucose-lowering medicines. <i>Journal of Research in Pharmacy Practice</i> , 2015, 4, 64.	0.2	6
498	Effect of empagliflozin on myocardial structure and function in patients with type 2 diabetes at high cardiovascular risk: the SIMPLE randomized clinical trial. <i>International Journal of Cardiovascular Imaging</i> , 2021, , 1.	0.7	6
499	Efficacy and Safety of Dapagliflozin in Patients With CKD Across Major Geographic Regions. <i>Kidney International Reports</i> , 2022, 7, 699-707.	0.4	6
500	Preventing diabetic nephropathy: an audit. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2001, 61, 471-477.	0.6	5
501	Effect of vitamin D on diabetic kidney disease in T1DM. <i>Nature Reviews Endocrinology</i> , 2013, 9, 6-7.	4.3	5
502	Several Conventional Risk Markers Suggesting Presence of Albuminuria Are Weak Among Rural Africans With Hypertension. <i>Journal of Clinical Hypertension</i> , 2016, 18, 27-30.	1.0	5
503	Inflammation Leads the Way on the ROADMAP to Diabetic Kidney Disease. <i>Kidney International Reports</i> , 2019, 4, 1362-1365.	0.4	5
504	Cardiac ventricular sizes are reduced in patients with long-term, normoalbuminuric type 1 diabetes compared to the non-diabetic background population. <i>Diabetes and Vascular Disease Research</i> , 2019, 16, 289-296.	0.9	5

#	ARTICLE	IF	CITATIONS
505	Clinical Features and Natural Course of Diabetic Nephropathy. , 2019, , 21-32.		5
506	Irbesartan treatment does not influence plasma levels of the dicarbonyls methylglyoxal, glyoxal and 3-oxo-deoxyglucosone in participants with type 2 diabetes and microalbuminuria: An IRMA2 substudy. Diabetic Medicine, 2021, 38, e14405.	1.2	5
507	Comparison of Natriuretic Peptides as Risk Markers for All-Cause Mortality and Cardiovascular and Renal Complications in Individuals With Type 1 Diabetes. Diabetes Care, 2021, 44, 595-603.	4.3	5
508	A narrative review of new treatment options for chronic kidney disease in type 2 diabetes. Annals of Translational Medicine, 2021, 9, 716-716.	0.7	5
509	Effect of Liraglutide on Vascular Inflammation Evaluated by [64Cu]DOTATATE. Diagnostics, 2021, 11, 1431.	1.3	5
510	The importance of addressing multiple risk markers in type 2 diabetes: Results from the <scp>LEADER</scp> and <scp>SUSTAIN</scp> 6 trials. Diabetes, Obesity and Metabolism, 2022, 24, 281-288.	2.2	5
511	Copeptin and renal function decline, cardiovascular events and mortality in type 1 diabetes. Nephrology Dialysis Transplantation, 2020, , .	0.4	5
512	Impact of random variation in albuminuria and estimated glomerular filtration rate on patient enrolment and duration of clinical trials in nephrology. Diabetes, Obesity and Metabolism, 2022, 24, 983-990.	2.2	5
513	Microalbuminuria Constitutes a Clinical Action Item for Clinicians in 2021. American Journal of Medicine, 2022, 135, 576-580.	0.6	5
514	Monitoring kidney function in diabetic nephropathy. Diabetologia, 1994, 37, 708-712.	2.9	5
515	Design of a randomised controlled trial of the effects of empagliflozin on myocardial perfusion, function and metabolism in type 2 diabetes patients at high cardiovascular risk (the SIMPLE trial). BMJ Open, 2019, 9, e029098.	0.8	5
516	Novel topical allogeneic bone-marrow-derived mesenchymal stem cell treatment of hard-to-heal diabetic foot ulcers: a proof of concept study. Stem Cell Research and Therapy, 2022, 13, .	2.4	5
517	Sodium-glucose cotransporter 2 inhibitors as adjunct therapy for type 1 diabetes and the benefit on cardiovascular and renal disease evaluated by Steno risk engines. Journal of Diabetes and Its Complications, 2022, 36, 108257.	1.2	5
518	Renoprotective effects of renin-angiotensin-system inhibitors. Lancet, The, 2006, 367, 898-899.	6.3	4
519	Impact of renin angiotensin system blockade on night to day blood pressure ratio in diabetic nephropathy. Nephrology Dialysis Transplantation, 2006, 21, 2030-2031.	0.4	4
520	Comparison of the Effects of Vitamins and/or Mineral Supplementation on Glomerular and Tubular Dysfunction in Type 2 Diabetes: Response to Farvid et al.. Diabetes Care, 2006, 29, 747-748.	4.3	4
521	Experimental testing of skin reactions to insulin detemir in diabetes patients naïve to insulin detemir. Skin Research and Technology, 2011, 17, 411-419.	0.8	4
522	Urinary Alpha- and Pi-Glutathione S-Transferases in Adult Patients with Type 1 Diabetes. Nephron Extra, 2014, 4, 127-133.	1.1	4

#	ARTICLE	IF	CITATIONS
523	Higher Parathyroid Hormone Level Is Associated With Increased Arterial Stiffness in Type 1 Diabetes. <i>Diabetes Care</i> , 2017, 40, e32-e33.	4.3	4
524	Effects of the Glucagon-Like Peptide-1 (GLP-1) Analogues Semaglutide and Liraglutide on Renal Outcomes – A Pooled Analysis of the Sustain 6 and Leader Trials. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, .	0.4	4
525	Effects of Semaglutide and Liraglutide on Urinary Albumin-to-Creatinine Ratio (UACR) – A Pooled Analysis of Sustain 6 and Leader. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, .	0.4	4
526	Changes in diabetes distress among people with type 2 diabetes during a risk screening programme for diabetic kidney disease – Longitudinal observations of the PRIORITY study. <i>Journal of Diabetes and Its Complications</i> , 2020, 34, 1074-1077.	1.2	4
527	Sex differences in the association between myocardial function and prognosis in type 1 diabetes without known heart disease: the Thousand & 1 Study. <i>European Heart Journal Cardiovascular Imaging</i> , 2021, 22, 1017-1025.	0.5	4
528	Lipoprotein(a) and renal function decline, cardiovascular disease and mortality in type 2 diabetes and microalbuminuria. <i>Journal of Diabetes and Its Complications</i> , 2020, 34, 1075-1083.	1.2	4
529	Relationship between peripheral neuropathy, diastolic function and adverse cardiovascular outcome in individuals with type 1 diabetes mellitus without known cardiovascular disease: Results from the Thousand & 1 Study. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 158-165.	2.2	4
530	Non-invasive assessment of temporal changes in myocardial microvascular function in persons with type 2 diabetes and healthy controls. <i>Diabetic Medicine</i> , 2021, 38, e14517.	1.2	4
531	The Association Between Cardiovascular Autonomic Function and Changes in Kidney and Myocardial Function in Type 2 Diabetes and Healthy Controls. <i>Frontiers in Endocrinology</i> , 2021, 12, 780679.	1.5	4
532	Kidney oxygenation, perfusion and blood flow in people with and without type 1 diabetes. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 2072-2080.	1.4	4
533	Impact of glycaemic control on the effect of direct renin inhibition in the AVOID study. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2012, 13, 250-253.	1.0	3
534	Discrepancy Between Tonometric Ambulatory and Cuff-Based Office Blood Pressure Measurements in Patients With Type 1 Diabetes. <i>Journal of Clinical Hypertension</i> , 2012, 14, 686-693.	1.0	3
535	An echocardiographic substrate for dyspnea identifies high risk patients with type 2 diabetes. <i>International Journal of Cardiology</i> , 2019, 289, 119-124.	0.8	3
536	Increasing ESKD in Diabetes in the Land Down Under: What Can Be Done, We Must Wonder. <i>American Journal of Kidney Diseases</i> , 2019, 73, 293-296.	2.1	3
537	Association between severe diabetic retinopathy and lectin pathway proteins – an 18-year follow-up study with newly diagnosed type 1 diabetes patients. <i>Immunobiology</i> , 2020, 225, 1519-1539.	0.8	3
538	Endothelial glycocalyx and cardio-renal risk factors in type 1 diabetes. <i>PLoS ONE</i> , 2021, 16, e0254859.	1.1	3
539	Left ventricular remodelling and cardiac chamber sizes in long-term, normoalbuminuric type 1 diabetes patients with and without cardiovascular autonomic neuropathy. <i>Journal of Diabetes and Its Complications</i> , 2019, 33, 171-177.	1.2	3
540	Making Use of Comparable Health Data to Improve Quality of Care and Outcomes in Diabetes: The EUBIROD Review of Diabetes Registries and Data Sources in Europe. <i>Frontiers in Clinical Diabetes and Healthcare</i> , 2021, 2, .	0.3	3

#	ARTICLE	IF	CITATIONS
541	Metabolomic and Proteomic Techniques for Establishing Biomarkers and Improving Our Understanding of Pathophysiology in Diabetic Nephropathy. <i>Methods in Molecular Biology</i> , 2020, 2067, 287-306.	0.4	3
542	Design of a randomised controlled trial of the effects of empagliflozin on myocardial perfusion, function and metabolism in type 2 diabetes patients at high cardiovascular risk (the SIMPLE trial). <i>BMJ Open</i> , 2019, 9, e029098.	0.8	3
543	Acute and Long-Term Treatment With Dapagliflozin and Association With Serum Soluble Urokinase Plasminogen Activator Receptor. <i>Frontiers in Pharmacology</i> , 2022, 13, 799915.	1.6	3
544	FC 123: Baseline Characteristics of the Flow Trial Population: Kidney Outcomes Trial With Once-Weekly Semaglutide in People With Type 2 Diabetes and Chronic Kidney Disease. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.4	3
545	Subclassification of diabetes based on quantitative traits. <i>Nature Reviews Nephrology</i> , 2018, 14, 355-356.	4.1	2
546	Improvements in albuminuria and chronic kidney disease progression with the appetite suppressant lorcaserin. <i>Kidney International</i> , 2019, 95, 1287-1288.	2.6	2
547	Response to Comment on Pilemann-Lyberg et al. Uric Acid Is an Independent Risk Factor for Decline in Kidney Function, Cardiovascular Events, and Mortality in Patients With Type 1 Diabetes. <i>Diabetes Care</i> 2019;42:1088-1094. <i>Diabetes Care</i> , 2019, 42, e188-e188.	4.3	2
548	A primer on metabolic memory: why existing diabetes treatments fail. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 756-767.	1.4	2
549	Prognostic and comparative performance of cardiovascular risk markers in patients with type 2 diabetes. <i>Journal of Diabetes</i> , 2021, 13, 754-763.	0.8	2
550	Biomarkers for early detection of kidney disease: a call for pathophysiological relevance. <i>Kidney International</i> , 2021, 99, 1240-1241.	2.6	2
551	FC 090EFFECTS OF FINERENONE ON CARDIORENAL OUTCOMES IN BLOOD PRESSURE SUBGROUPS IN PATIENTS WITH CKD AND T2D. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.4	2
552	The History of Prevention and Treatment of Diabetic Nephropathy. <i>Frontiers in Diabetes</i> , 2020, , 242-256.	0.4	2
553	Association between plasma apolipoprotein M and cardiac autonomic neuropathy in type 1 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2022, 189, 109943.	1.1	2
554	Concentration changes during venous occlusion of proteins with affinity for extracellular matrix in insulin-dependent diabetes mellitus a sign of vascular damage in patients with diabetic nephropathy?. <i>Fibrinolysis and Proteolysis</i> , 1999, 13, 142-147.	1.1	1
555	Is renal Na ⁺ ,K ⁺ -ATPase a new target for renin-angiotensin blocking agents in diabetic nephropathy?. <i>Journal of Physiology</i> , 2008, 586, 5283-5283.	1.3	1
556	UACR—two risk markers or a 24 h collection in a minute?. <i>Nature Reviews Nephrology</i> , 2012, 8, 320-321.	4.1	1
557	Can ADAMTS13 Lead Us to the Paradise of Personalized Medicine?. <i>Diabetes</i> , 2013, 62, 3331-3332.	0.3	1
558	OP60 EFFICACY AND SAFETY OF LIRAGLUTIDE VERSUS PLACEBO IN SUBJECTS WITH TYPE 2 DIABETES AND MODERATE RENAL IMPAIRMENT (LIRA-RENAL): A RANDOMISED TRIAL. <i>Diabetes Research and Clinical Practice</i> , 2014, 106, S31.	1.1	1

#	ARTICLE	IF	CITATIONS
559	TMAO: Trimethylamine-N-Oxide or Time to Minimize Intake of Animal Products?. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e4958-e4960.	1.8	1
560	Response to Comment on Vistisen et al. A Validated Prediction Model for End-Stage Kidney Disease in Type 1 Diabetes. Diabetes Care 2021;44:901â€“907. Diabetes Care, 2021, 44, e140-e141.	4.3	1
561	Successful glucose lowering therapy triumphs in heart failure. EclinicalMedicine, 2021, 37, 100996.	3.2	1
562	HbA1c and beyond. Nephrology Dialysis Transplantation, 2023, 38, 34-40.	0.4	1
563	40-LB: Association between Complement and Severe Retinal Complications in Type 1 Diabetesâ€”An 18-Year Follow-Up Study. Diabetes, 2019, 68, 40-LB.	0.3	1
564	28-LB: Improved Time in Glucose Range over One Year Is Associated with Reduced Albuminuria in Sensor-Augmented Insulin Pumpâ€”Treated Type 1 Diabetes. Diabetes, 2020, 69, .	0.3	1
565	1615-P: Predicting End-Stage Kidney Disease in Type 1 Diabetes. Diabetes, 2020, 69, .	0.3	1
566	What Have We Learned so Far From the Use of Sodium-Glucose Cotransporter 2 Inhibitors in Clinical Practice?. Advances in Chronic Kidney Disease, 2021, 28, 290-297.	0.6	1
567	The authors reply:. Kidney International, 2022, 101, 420-421.	2.6	1
568	The effect of liraglutide on cardiac autonomic function in type 2 diabetes: A prespecified secondary analysis from the <scp>LIRAFLAME</scp> randomized, doubleâ€”blinded, placeboâ€”controlled trial. Diabetes, Obesity and Metabolism, 2022, 24, 1638-1642.	2.2	1
569	FC083: Finerenone and Canagliflozin in the Treatment of Chronic Kidney Disease and Type 2 Diabetes: Matching-Adjusted Indirect Treatment Comparison of Fidelio-DKD and Credence. Nephrology Dialysis Transplantation, 2022, 37, .	0.4	1
570	Prevention and treatment of diabetic nephropathy with blood pressure lowering drugs. Nephrology, 1996, 2, s45-s48.	0.7	0
571	Role of Plasma Homocysteine and Plasminogen Activator Inhibitor-1 in the Progression of Diabetic Nephropathy. , 2002, , 97-101.		0
572	RNA oxidation and albuminuria in type 1 diabetes patients. Cardiovascular Endocrinology, 2013, 2, 103-105.	0.8	0
573	PP.33.31. Journal of Hypertension, 2015, 33, e437.	0.3	0
574	PP.33.30. Journal of Hypertension, 2015, 33, e436-e437.	0.3	0
575	[OP.1D.10] THE CKD273 URINARY PROTEOMIC CLASSIFIER IS NOT A MARKER OF GENERALISED VASCULAR DISEASE IN TYPE 2 DIABETIC PATIENTS WITH NORMAL RENAL FUNCTION. Journal of Hypertension, 2016, 34, e14.	0.3	0
576	[OP.4B.04] URINARY PROTEOMICS PREDICTS MORTALITY IN TYPE 2 DIABETES PATIENTS WITH MICROALBUMINURIA. Journal of Hypertension, 2017, 35, e38-e39.	0.3	0

#	ARTICLE	IF	CITATIONS
577	SP417EFFECT OF DAPAGLIFLOZIN ON ALBUMINURIA AND THE RENIN-ANGIOTENSIN SYSTEM WHEN ADDED TO RENIN-ANGIOTENSIN BLOCKADE IN PATIENTS WITH TYPE 2 DIABETES AND NEPHROPATHY. Nephrology Dialysis Transplantation, 2018, 33, i488-i488.	0.4	0
578	SP420ALTERED LEVELS OF PLASMA LIPIDS ARE ASSOCIATED WITH DIABETIC KIDNEY DISEASE: A CROSS-SECTIONAL STUDY OF PLASMA LIPIDOMICS IN TYPE 1 DIABETES. Nephrology Dialysis Transplantation, 2018, 33, i489-i489.	0.4	0
579	A3993 Myocardial flow reserve assessed by Cardiac 82Rb PET/CT is associated with albumin excretion in patients with type 1 diabetes. Journal of Hypertension, 2018, 36, e147.	0.3	0
580	SEX-SPECIFIC REGULATION OF URINARY PEPTIDES IN EARLY DIABETIC NEPHROPHY. Journal of Hypertension, 2018, 36, e240.	0.3	0
581	Aldosterone Blockade Added to Renin-Angiotensin System Blockade to Reduce Albuminuriaâ€”A Path for Improved Renoprotection?. American Journal of the Medical Sciences, 2018, 355, 407-408.	0.4	0
582	3080Postsystolic shortening yields novel and independent prognostic information on cardiovascular events and mortality in patients with type 2 diabetes. European Heart Journal, 2019, 40, .	1.0	0
583	OBESITY REMAINS A MAJOR RISK FACTOR ASSOCIATED WITH VASCULAR STIFFENING IN TYPE 2 DIABETES. Journal of Hypertension, 2019, 37, e65.	0.3	0
584	Mineralocorticoid Receptor Antagonists for Diabetic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 1696-1698.	2.2	0
585	Serum Creatinine and Other Measures of GFR in Diabetes. , 2000, , 95-101.		0
586	Serum Creatinine and other Measures of GFR in Diabetes. , 1998, , 97-102.		0
587	How Does Risk Screening for Kidney Disease Influence Diabetes Distress?. Diabetes, 2018, 67, .	0.3	0
588	237-OR: Beneficial Impact of Intensified Multifactorial Intervention on Strokeâ€”The Steno-2 Study. Diabetes, 2019, 68, 237-OR.	0.3	0
589	456-P: The REMOVAL Trial: Effect of Metformin on Markers of Cardiometabolic Risk in Patients with Type 1 Diabetes. Diabetes, 2019, 68, 456-P.	0.3	0
590	526-P: Dapagliflozin Improves the Urinary CKD273 Proteomic Score When Added to Renin-Angiotensin Blockade in Patients with Type 2 Diabetes and Nephropathy. Diabetes, 2019, 68, 526-P.	0.3	0
591	490-P: Renal Effects of Metformin in Type 1 Diabetes (T1D): The REMOVAL Trial. Diabetes, 2020, 69, .	0.3	0
592	1532-P: Investigating Biomarkers of the Immune Response and Tissue Remodeling in Patients with Type 2 Diabetes with Microalbuminuria. Diabetes, 2020, 69, 1532-P.	0.3	0
593	Prognostic utility of early systolic lengthening by speckle tracking echocardiography in patients with type 2 diabetes. European Heart Journal, 2020, 41, .	1.0	0
594	Abstract 14182: Genome Wide Association Study for High Sensitive Cardiac Troponin T Levels Identifies a Novel Gene in Europeans With Type 1 Diabetes. Circulation, 2020, 142, .	1.6	0

#	ARTICLE	IF	CITATIONS
595	Cardiac time intervals predict major adverse cardiovascular events in individuals with type 1 diabetes without known heart disease. <i>European Heart Journal</i> , 2020, 41, .	1.0	0
596	Liraglutide Lowers Palmitoleate Levels in Type 2 Diabetes. A Post Hoc Analysis of the LIRAFLAME Randomized Placebo-Controlled Trial. <i>Frontiers in Clinical Diabetes and Healthcare</i> , 2022, 3, .	0.3	0
597	Title is missing!. , 2020, 15, e0243737.		0
598	Title is missing!. , 2020, 15, e0243737.		0
599	Title is missing!. , 2020, 15, e0243737.		0
600	Title is missing!. , 2020, 15, e0243737.		0
601	Title is missing!. , 2020, 15, e0243737.		0
602	Title is missing!. , 2020, 15, e0243737.		0
603	Title is missing!. , 2020, 15, e0243737.		0
604	Title is missing!. , 2020, 15, e0243737.		0
605	FC082: Effects of Dapagliflozin in Patients with Chronic Kidney Disease According to Background Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Dose. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.4	0
606	MO198: Outcomes with Finerenone in Patients with Stage 4 Chronic Kidney Disease and Type 2 Diabetes: A Fidelity Subgroup Analysis. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.4	0
607	Diagnostic and prognostic value of the electrocardiogram in stable outpatients with type 2 diabetes. <i>Scandinavian Cardiovascular Journal</i> , 2022, 56, 256-263.	0.4	0